SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
☒ |
Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2015 |
or
|
|
☐ |
Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to |
Commission File Number: 000-20086
UNIVERSAL HOSPITAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
41-0760940 |
(State or other jurisdiction of |
|
(I.R.S. Employer |
incorporation or organization) |
|
Identification No.) |
6625 West 78th Street, Suite 300
Minneapolis, Minnesota 55439-2604
(Address of principal executive offices, including zip code)
(952) 893-3200
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☐ |
(Do not check if a smaller reporting company) |
|
|
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Number of shares of co mmon stock outstanding as of May 13, 2015 : 1,000
Universal Hospital Services, Inc.
1
PART I - FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements — Unaudited
Universal Hospital Services, Inc.
(in thousands, except share and per share information)
(unaudited)
|
|
|
|
|
|
|
|
|
March 31, |
|
December 31, |
||
|
|
2015 |
|
2014 |
||
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Accounts receivable, less allowance for doubtful accounts of $1,900 at March 31, 2015 and $2,035 at December 31, 2014 |
|
$ |
|
|
$ |
|
Inventories |
|
|
|
|
|
|
Deferred income taxes, net |
|
|
|
|
|
|
Other current assets |
|
|
|
|
|
|
Total current assets |
|
|
|
|
|
|
Property and equipment: |
|
|
|
|
|
|
Medical equipment |
|
|
|
|
|
|
Property and office equipment |
|
|
|
|
|
|
Accumulated depreciation |
|
|
|
|
|
|
Total property and equipment, net |
|
|
|
|
|
|
Other long-term assets: |
|
|
|
|
|
|
Goodwill |
|
|
|
|
|
|
Other intangibles, net |
|
|
|
|
|
|
Other, primarily deferred financing costs, net |
|
|
|
|
|
|
Total assets |
|
$ |
|
|
$ |
|
Liabilities and Deficit |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Current portion of long-term debt |
|
$ |
|
|
$ |
|
Book overdrafts |
|
|
|
|
|
|
Accounts payable |
|
|
|
|
|
|
Accrued compensation |
|
|
|
|
|
|
Accrued interest |
|
|
|
|
|
|
Dividend payable |
|
|
|
|
|
|
Other accrued expenses |
|
|
|
|
|
|
Total current liabilities |
|
|
|
|
|
|
Long-term debt, less current portion |
|
|
|
|
|
|
Pension and other long-term liabilities |
|
|
|
|
|
|
Payable to Parent |
|
|
|
|
|
|
Deferred income taxes, net |
|
|
|
|
|
|
Commitments and contingencies (Note 9) |
|
|
|
|
|
|
Deficit |
|
|
|
|
|
|
Common stock, $0.01 par value; 1,000 shares authorized, issued and outstanding at March 31, 2015 and December 31, 2014 |
|
|
— |
|
|
— |
Additional paid-in capital |
|
|
|
|
|
|
Accumulated deficit |
|
|
|
|
|
|
Accumulated other comprehensive loss |
|
|
|
|
|
|
Total Universal Hospital Services, Inc. deficit |
|
|
|
|
|
|
Noncontrolling interest |
|
|
|
|
|
|
Total deficit |
|
|
|
|
|
|
Total liabilities and deficit |
|
$ |
|
|
$ |
|
The accompanying notes are an integral part of the unaudited consolidated financial statements.
2
Universal Hospital Services, Inc.
Consolidated Statements of Operation s
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
||||
|
|
March 31, |
|
||||
|
|
2015 |
|
2014 |
|
||
Revenue |
|
|
|
|
|
|
|
Medical equipment solutions |
|
$ |
|
|
$ |
|
|
Clinical engineering solutions |
|
|
|
|
|
|
|
Surgical services |
|
|
|
|
|
|
|
Total revenues |
|
|
|
|
|
|
|
Cost of Revenue |
|
|
|
|
|
|
|
Cost of medical equipment solutions |
|
|
|
|
|
|
|
Cost of clinical engineering solutions |
|
|
|
|
|
|
|
Cost of surgical services |
|
|
|
|
|
|
|
Medical equipment depreciation |
|
|
|
|
|
|
|
Total costs of revenues |
|
|
|
|
|
|
|
Gross margin |
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
|
|
|
|
|
Restructuring, acquisition and integration expenses |
|
|
— |
|
|
|
|
Operating income |
|
|
|
|
|
|
|
Interest expense |
|
|
|
|
|
|
|
Loss before income taxes and noncontrolling interest |
|
|
|
|
|
|
|
Provision for income taxes |
|
|
|
|
|
|
|
Consolidated net loss |
|
|
|
|
|
|
|
Net income attributable to noncontrolling interest |
|
|
|
|
|
|
|
Net loss attributable to Universal Hospital Services, Inc. |
|
$ |
|
|
$ |
|
|
The accompanying notes are an integral part of the unaudited consolidated financial statements.
3
Universal Hospital Services, Inc.
Consolidated Statements of Comprehensive Los s
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
||||
|
|
March 31, |
|
||||
|
|
2015 |
|
2014 |
|
||
Consolidated net loss |
|
$ |
|
|
$ |
|
|
Total other comprehensive income |
|
|
— |
|
|
— |
|
Comprehensive loss |
|
|
|
|
|
|
|
Comprehensive income attributable to noncontrolling interest |
|
|
|
|
|
|
|
Comprehensive loss attributable to Universal Hospital Services, Inc. |
|
$ |
|
|
$ |
|
|
The accompanying notes are an integral part of the unaudited consolidated financial statements.
4
Universal Hospital Services, Inc.
Consolidated Statements of Cash Flow s
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
Three Months Ended |
||||
|
|
March 31, |
||||
|
|
2015 |
|
2014 |
||
Cash flows from operating activities: |
|
|
|
|
|
|
Consolidated net loss |
|
$ |
|
|
$ |
|
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
|
|
|
Depreciation |
|
|
|
|
|
|
Assets impairment charges |
|
|
|
|
|
|
Amortization of intangibles, deferred financing costs and bond premium |
|
|
|
|
|
|
Provision for doubtful accounts |
|
|
|
|
|
|
Provision for inventory obsolescence |
|
|
|
|
|
|
Non-cash share-based compensation expense |
|
|
|
|
|
|
Gain on sales and disposals of equipment |
|
|
|
|
|
|
Deferred income taxes |
|
|
|
|
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
|
|
Inventories |
|
|
|
|
|
|
Other operating assets |
|
|
|
|
|
|
Accounts payable |
|
|
|
|
|
|
Other operating liabilities |
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
Medical equipment purchases |
|
|
|
|
|
|
Property and office equipment purchases |
|
|
|
|
|
|
Proceeds from disposition of property and equipment |
|
|
|
|
|
|
Net cash used in investing activities |
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
Proceeds under senior secured credit facility |
|
|
|
|
|
|
Payments under senior secured credit facility |
|
|
|
|
|
|
Payments of principal under capital lease obligations |
|
|
|
|
|
|
Distributions to noncontrolling interests |
|
|
|
|
|
|
Dividend and equity distribution payments |
|
|
|
|
|
|
Change in book overdrafts |
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
|
|
|
|
Net change in cash and cash equivalents |
|
|
— |
|
|
— |
Cash and cash equivalents at the beginning of period |
|
|
— |
|
|
— |
Cash and cash equivalents at the end of period |
|
$ |
— |
|
$ |
— |
Supplemental cash flow information: |
|
|
|
|
|
|
Interest paid |
|
$ |
|
|
$ |
|
Income taxes paid |
|
|
|
|
|
|
Non-cash activities: |
|
|
|
|
|
|
Medical equipment purchases included in accounts payable (at end of period) |
|
$ |
|
|
$ |
|
Capital lease additions |
|
|
|
|
|
|
Reclassification of assets held for sale from medical equipment to other current assets |
|
|
— |
|
|
|
The accompanying notes are an integral part of the unaudited consolidated financial statements.
5
Universal Hospital Services, Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Basis of Presentation
The interim consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared by Universal Hospital Services, Inc. (“we”, “our”, “us”, the “Company”, or “UHS”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the financial statements and related notes included in the Company’s 2014 Annual Report on Form 10-K filed with the SEC.
The interim consolidated financial statements presented herein as of March 31, 2015 , reflect, in the opinion of management, all adjustments necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. These adjustments are all of a normal, recurring nature. The results of operations for any interim period are not necessarily indicative of results for the full year.
We are required to make estimates and assumptions about future events in preparing consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the amounts of assets, liabilities, revenues and expenses at the date of the unaudited consolidated financial statements. While we believe that our past estimates and assumptions have been materially accurate, our current estimates are subject to change if different assumptions as to the outcome of future events are made. We evaluate our estimates and judgments on an ongoing basis and predicate those estimates and judgments on historical experience and on various other factors that we believe to be reasonable under the circumstances. We make adjustments to our assumptions and judgments when facts and circumstances dictate. Since future events and their effects cannot be determined with absolute certainty, actual results may differ from the estimates used in preparing the accompanying unaudited consolidated financial statements.
A description of our significant accounting policies is included in our 2014 Annual Report on Form 10-K. There have been no material changes to these policies for the quarter ended March 31, 2015 .
Principles of Consolidation
The consolidated financial statements include the accounts of UHS and its 100% -owned subsidiary, UHS Surgical Services, Inc. (“Surgical Services”). In addition, in accordance with guidance issued by the Financial Accounting Standards Board (“FASB”), we have accounted for our equity investments in entities in which we are the primary beneficiary under the full consolidation method. All significant intercompany transactions and balances have been eliminated through consolidation. As the primary beneficiary, we consolidate the limited liability companies (“LLCs”) referred to in Note 11, Limited Liability Companies, as we effectively receive the majority of the benefits from such entities and we provide equipment lease guarantees for such entities.
2. Recent Accounting Pronouncements
Standard s Not Yet Adopted
In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in the U.S. GAAP when it becomes effective. The new standard is effective beginning after December 15, 2016 and interim periods within those years. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting . On April 1, 2015, the FASB tentatively agreed to propose a one-year deferral of the effective date for ASU 2014-09, but would permit all entities to adopt the standard as of the original effective date.
6
In August 2014, the FASB issued ASU No. 2014-15 Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties a bout an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which requires management to evaluate the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern and whether or not it is probable that the entity will be unable to meet its obligations as they become due within one year after the date the financial statements are issued. The new standard is effective beginning after December 15, 2016 and interim periods within those years. Early adoption is permitted. We are evaluating the effect that ASU 2014-15 will have on our consolidated financial statements and related disclosures.
In February 2015, the FASB issued ASU No. 2015-02 Amendments to the Consolidation Analysis (“ASU 2015-02”). ASU 2015-02 changes the evaluation of whether limited partnerships (and similar legal entities) are variable interest entity (VIEs) and eliminates the presumption that a general partner should consolidate a limited partnership that is a voting interest entity. The new guidance also alters the analysis for determining when fees paid to a decision maker or service provider represent a variable interest in a VIE and how interests of related parties affect the primary beneficiary determination. The ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2015. Early adoption is permitted. We are evaluating the effect that ASU 2015-02 will have on our consolidated financial statements and related disclosures.
In April 2015, the FASB issued ASU No. 2015-03 Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2015. Early adoption is permitted. We are evaluating the effect that ASU 2015-02 will have on our consolidated financial statements and related disclosures.
3. Fair Value Measurements
Financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014 are summarized in the following table by type of inputs applicable to the fair value measurements:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value at March 31, 2015 |
|
Fair Value at December 31, 2014 |
||||||||||||||||||||
(in thousands) |
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
|
Level 1 |
|
Level 2 |
|
Level 3 |
|
Total |
||||||||
Contingent Consideration |
|
$ |
— |
|
$ |
— |
|
$ |
|
|
$ |
|
|
$ |
— |
|
$ |
— |
|
$ |
|
|
$ |
|
A description of the inputs used in the valuation of assets and liabilities is summarized as follows:
Level 1 — Inputs represent unadjusted quoted prices for identical assets or liabilities exchanged in active markets.
Level 2 — Inputs include directly or indirectly observable inputs other than Level 1 inputs such as quoted prices for similar assets or liabilities exchanged in active or inactive markets; quoted prices for identical assets or liabilities exchanged in inactive markets; other inputs that are considered in fair value determinations of the assets or liabilities, such as interest rates and yield curves that are observable at commonly quoted intervals, volatilities, prepayment speeds, loss severities, credit risks and default rates; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
Level 3 — Inputs include unobservable inputs used in the measurement of assets and liabilities. Management is required to use its own assumptions regarding unobservable inputs because there is little, if any, market activity in the assets or liabilities or related observable inputs that can be corroborated at the measurement date. Measurements of non-exchange traded derivative contract assets and liabilities are primarily based on valuation models, discounted cash flow models or other valuation techniques that are believed to be used by market participants. Unobservable inputs require management to make certain projections and assumptions about the information that would be used by market participants in pricing assets or liabilities.
During 2012, we recorded a contingent consideration liability, in the form of an earn-out payment, related to our acquisitions. The contingent consideration payments are based on achieving certain revenue results. The fair value of the liability was estimated using a discounted cash flow approach with significant inputs that are not observable in the
7
market and thus represents a Level 3 fair value measurement . The significant inputs in the Level 3 measurement not supported by market activity included our assessments of expected future cash flows during the earn-out period, related to the assets acquired, appropriately discounted considering the uncertainties associated with the obligation, and calculated based on estimated revenues in accordance with the terms of the agreement. During the three months ended March 31, 2015 and 2014 , we paid $0.01 and $0.02 million , respectively, in earn-out s.
The assumptions used in preparing the discounted cash flow analysis included estimates of interest rates and the timing and amount of incremental cash flows.
A reconciliation of the beginning and ending balance for the Level 3 measurement are as follows:
|
|
|
|
(in thousands) |
|
|
|
Balance at December 31, 2014 |
|
$ |
|
Payments |
|
|
|
Balance at March 31, 2015 |
|
$ |
|
During the three months ended March 31, 2015 and 2014 , we recorded $1.7 and $ 1.2 million of impairment charge on certain long-lived assets for which the carrying value of those assets may not be recoverable based upon our estimated cash flows. The fair value of the assets was estimated using a discounted cash flow approach with significant inputs that are not observable i n the market and thus represents a Level 3 fair value measurement. The significant inpu ts in the Level 3 measurement no t supported by market activity included our assessment of assets utilization level and estimated proceeds from sale of the assets.
Fair Value of Other Financial Instruments
The Company considers that the carrying amount of financial instruments, including accounts receivable, accounts payable, accrued liabilities and senior secured credit facility, approximates fair value due to their short maturities. The fair value of our outstanding Original Notes and Add-on Notes (each as defined in Note 8, Long-Term Debt) as of March 31, 2015 and December 31, 2014 , based on the quoted market price for the same or similar issues of debt, which represents a Level 2 fair value measurement, is approximately:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2015 |
|
December 31, 2014 |
||||||||
|
|
Carrying |
|
Fair |
|
Carrying |
|
Fair |
||||
(in millions) |
|
Value |
|
Value |
|
Value |
|
Value |
||||
Original notes - 7.625% |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Add-on notes - 7.625% (1) |
|
|
|
|
|
|
|
|
|
|
|
|
(1) The carrying value of the Add-on notes - 7.625% includes unamortized bond premium of $10.7 and $11.1 million as of March 31, 2015 and December 31, 2014 , respectively.
4. Goodwill and Other Intangible Assets
Our goodwill as of March 31, 2015 and December 31, 2014 , by reporting segment, consists of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical |
|
Clinical |
|
|
|
|
|
|||
|
|
Equipment |
|
Engineering |
|
Surgical |
|
|
|
|||
(in thousands) |
|
Solutions |
|
Solutions |
|
Services |
|
Total |
||||
Balance at December 31, 2014 |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Acquisitions |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Balance at March 31, 2015 |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
8
Our other intangible assets as of March 31, 2015 and December 31, 2014 consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2015 |
|
December 31, 2014 |
||||||||||||||||||||
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
||||||||
(in thousands) |
|
Cost |
|
Amortization |
|
Impairment |
|
Net |
|
Cost |
|
Amortization |
|
Impairment |
|
Net |
||||||||
Finite-life intangibles |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer relationship |
|
$ |
|
|
$ |
|
|
$ |
— |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
— |
|
$ |
|
Supply agreement |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
Technology databases |
|
|
|
|
|
|
|
|
— |
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
— |
Non-compete agreements |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
Favorable lease agreements |
|
|
|
|
|
|
|
|
— |
|
|
— |
|
|
|
|
|
|
|
|
— |
|
|
— |
Total finite-life intangibles |
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
Indefinite-life intangibles |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade names |
|
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
Total intangible assets |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Total amortization expense related to intangible assets were $3.1 and $3.3 million for the three months ended March 31, 2015 and 2014 , respectively .
The estimated future amortization expense for identifiable intangible assets during the remainder of 2015 and the next five years is as follows:
|
|
|
|
(in thousands) |
|
|
|
Remainder of 2015 |
|
$ |
|
2016 |
|
|
|
2017 |
|
|
|
2018 |
|
|
|
2019 |
|
|
|
2020 |
|
|
|
5. Equit y (Deficit)
The following tables represent changes in equity (deficit) that are attributable to our shareholders and noncontrolling interests for the three month periods ended March 31, 2015 and 2014 .
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
||
|
|
Additional |
|
|
|
|
Other |
|
|
|
|
|
|||
|
|
Paid-in |
|
Accumulated |
|
Comprehensive |
|
Noncontrolling |
|
Total |
|||||
(in thousands) |
|
Capital |
|
Deficit |
|
Loss |
|
Interests |
|
Deficit |
|||||
Balance at December 31, 2014 |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Net (loss) income |
|
|
— |
|
|
|
|
|
— |
|
|
|
|
|
|
Cash distributions to noncontrolling interests |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
|
Balance at March 31, 2015 |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
||
|
|
Additional |
|
|
|
|
Other |
|
|
|
|
|
|
||
|
|
Paid-in |
|
Accumulated |
|
Comprehensive |
|
Noncontrolling |
|
Total |
|||||
(in thousands) |
|
Capital |
|
Deficit |
|
Loss |
|
Interests |
|
Equity |
|||||
Balance at December 31, 2013 |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Net (loss) income |
|
|
— |
|
|
|
|
|
— |
|
|
|
|
|
|
Cash distributions to noncontrolling interests |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
|
Balance at March 31, 2014 |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
9
6. Share-Based Compensation
During the three months ended March 31, 2015 , activity under the 2007 Stock Option Plan (the “2007 Stock Option Plan”), of UHS Holdco, Inc., our parent company (“Parent”), was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
|
|
|
|
average |
|
|
|
|
Weighted |
|
Aggregate |
|
remaining |
||
|
|
Number of |
|
average |
|
intrinsic |
|
contractual |
||
(in thousands except exercise price and years) |
|
options |
|
exercise price |
|
value |
|
term (years) |
||
Outstanding at December 31, 2014 |
|
|
|
$ |
|
|
$ |
— |
|
|
Granted |
|
|
|
|
|
|
|
|
|
|
Exercised |
|
— |
|
|
— |
|
$ |
— |
|
|
Forfeited or expired |
|
|
|
|
|
|
|
|
|
|
Outstanding at March 31, 2015 |
|
|
|
$ |
|
|
$ |
— |
|
|
Exercisable at March 31, 2015 |
|
|
|
$ |
|
|
$ |
— |
|
|
Remaining authorized options available for issue |
|
|
|
|
|
|
|
|
|
|
The exercise price of the stock option award is equal to the market value of Parent’s common stock on the grant date as determined reasonably and in good faith by Parent’s Board of Directors and compensation committee and based on an analysis of a variety of factors including peer group multiples, merger and acquisition multiples, and discounted cash flow analyses.
The intrinsic value of a stock award is the amount by which the market value of the underlying stock exceeds the exercise price of the award.
We determine the fair value of stock options using the Black-Scholes option pricing model. The estimated fair value of options, including the effect of estimated forfeitures, is recognized as expense on a straight-line basis over the options’ expected vesting periods. The following assumptions were used in determining the fair value of stock options granted during the three months ended March 31, 2015 under the Black-Scholes model. There were no stock options granted during the three months ended March 31, 2014 .
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, 2015 |
|
Risk-free interest rate |
|
|
% |
Expected volatility |
|
|
% |
Dividend yield |
|
N/A |
|
Expected option life (years) |
|
|
|
Black-Scholes Value of options |
$ |
|
|
Expected volatility is based on an independent valuation of the stock of companies within our peer group. Given the lack of a true comparable company, the peer group consists of selected public health care companies representing our suppliers, customers and competitors within certain product lines. The risk free-interest rate is based on the U.S. Treasury yield curve in effect at the grant date based on the expected option life. The expected option life is estimated based on foreseeable trends.
Although Parent grants stock options, the Company recognizes compensation expense related to these options since the services are performed for its benefit. Along with this expense, which is primarily included in Selling, General and Administrative expense, the Company records an offsetting Payable to Parent liability which is not expected to be settled within the next twelve months.
At March 31, 2015 , unearned non-cash share-based compensation that we expect to recognize as expense over a weighted average period of 2.2 years totals approximately $4.1 million, net of our estimated forfeiture rate of 2.0% . The expense could be accelerated upon the sale of Parent or the Company.
10
7. Dividend and Equity Distribution
On June 8, 2011, the Board of Directors declared an equity distribution of $0.12 per option to holders of outstanding options on the Parent’s stock on June 10, 2011 that vested on December 31, 2011, 2012 , 2013 and 2014 and are scheduled to vest on December 31, 2015.
Our consolidated balance sheets as of March 31, 2015 and December 31, 2014 reflect the related current dividend payable and long-term dividend payable included in Payable to Parent for estimated amounts to be paid to holders of options expected to vest on December 31, 2015 based on an estimated option forfeiture rate of 2% annually.
8. Long-Term Debt
Long-term debt consists of the following:
|
|
|
|
|
|
|
|
|
March 31, |
|
December 31, |
||
(in thousands) |
|
2015 |
|
2014 |
||
Original notes - 7.625% |
|
$ |
|
|
$ |
|
Add-on notes - 7.625% |
|
|
|
|
|
|
Unamortized bond premium |
|
|
|
|
|
|
Senior secured credit facility |
|
|
|
|
|
|
Capital lease obligations |
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: Current portion of long-term debt |
|
|
|
|
|
|
Total long-term debt |
|
$ |
|
|
$ |
|
Original Notes and Add-on Notes — 7.625%. On August 7, 2012, we issued $425.0 million in aggregate principal amount of 7.625 % Second Lien Senior Secured Notes due 2020 (the “Original Notes”) under an indenture dated as of August 7, 2012 (the “2012 Indenture”). On February 12, 2013, we issued $220.0 million in aggregate principal amount of 7.625 % Second Lien Senior Secured Notes due 2020 (the “Add-on Notes”, and along with the Original Notes, the “2012 Notes”) as “additional notes” pursuant to the 2012 Indenture . The 2012 Notes mature on August 15, 2020.
The 2012 Indenture provides that the 2012 Notes are our second lien senior secured obligations and are fully and unconditionally guaranteed on a second lien senior secured basis by our existing and certain of our future 100% -owned domestic subsidiaries.
Interest on the 2012 Notes is payable, entirely in cash, semiannually, in arrears, on February 15 and August 15 of each year, beginning on February 15, 2013. We may redeem some or all of the 2012 Notes at the redemption prices set forth in the 2012 Indenture. If we sell certain assets or undergo certain kinds of changes of control, we must offer to repurchase the 2012 Notes.
Our 2012 Notes are subject to certain debt covenants which are described below under the heading “2012 Indenture” .
Senior Secured Credit Facility. On July 31, 2012, we entered into a Second Amended and Restated Credit Agreement with Bank of America, N.A., as agent for the lenders, and the lenders party thereto (the “Second Amended Credit Agreement”), which amended our then-existing senior secured credit facility originally dated as of May 31, 2007 and amended and restated as of May 6, 2010. We refer to the second amended and restated senior secured credit facility as the “senior secured credit facility.” The senior secured credit facility is a first lien senior secured asset based revolving credit facility that is available for working capital and general corporate purposes, including permitted investments, capital expenditures and debt repayments, on a fully revolving basis, subject to the terms and conditions set forth in the credit documents in the form of revolving loans, swing line loans and letters of credit. The Second Amended Credit Agreement increased the aggregate amount we may obtain under revolving loans from $195.0 million to $235.0 million and extended the maturity date to July 31, 2017. Our obligations under the Second Amended Credit Agreement are secured by a first priority security interest in substantially all of our assets, excluding a pledge of our and Parent’s stock, any joint ventures and certain other exceptions. Our obligations under the Second Amended Credit Agreement are unconditionally guaranteed by P arent and our restricted subsidiaries.
11
As of March 31, 2015 , we had $123.6 million of availability under the senior secured credit facility based on a borrowing base of $177.2 million less borrowings of $50.0 million and after giving effect to $ 3.6 million used for letters of credit.
The senior secured credit facility requires our compliance with various affirmative and negative covenants. Pursuant to the affirmative covenants, we and Parent agreed to, among other things, deliver financial and other information to the administrative agent, provide notice of certain events (including events of default), pay our obligations, maintain our properties, maintain the security interest in the collateral for the benefit of the administrative agent and the lenders and maintain insurance.
Among other restrictions, and subject to certain definitions and exceptions, the senior secured credit facility restricts our ability to:
|
· |
|
incur indebtedness; |
|
· |
|
create or permit liens; |
|
· |
|
declare or pay dividends and certain other restricted payments; |
|
· |
|
consolidate, merge or recapitalize; |
|
· |
|
acquire or sell assets; |
|
· |
|
make certain investments, loans or other advances; |
|
· |
|
enter into transactions with affiliates; |
|
· |
|
change our line of business; and |
|
· |
|
enter into hedging transactions. |
The senior secured credit facility also contains a financial covenant that is triggered if our available borrowing capacity is less than $20.0 million for a certain period, which consists of a minimum ratio of trailing four -quarter Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) to cash interest expense, as such terms are defined in the senior secured credit facility.
The senior secured credit facility specifies certain events of default, including, among others, failure to pay principal, interest or fees, violation of covenants, inaccuracy of representations or warranties, bankruptcy events, certain ERISA-related events, cross-defaults to other material agreements, change of control events and invalidity of guarantees or security documents . Some events of default will be triggered only after certain cure periods have expired, or will provide for materiality thresholds. If such a default occurs, the lenders under the senior secured credit facility would be entitled to take various actions, including all actions permitted to be taken by a secured creditor and the acceleration of amounts due under the senior secured credit facility.
Borrowings under the senior secured credit facility accrue interest (including a credit spread varying with facility usage):
|
· |
|
at a per annum rate equal to 1.00% - 1.50% above the rate equal to the greater of (i) the “ federal funds rate ” plus one-half of one percent ( 0.50 %) per annum, (ii) the “prime rate” announced from time to time by the administrative agent for such day and (iii) the “ Eurodollar rate ” for a one month interest period as determined on such day, plus one percent ( 1.0 %) payable quarterly in arrears; and |
|
· |
|
at a per annum rate equal to 2.00% - 2.50% above the adjusted British Bankers Association Interest Settlement Rate for deposits in Dollars rate used by the administrative agent with a term equivalent to the selected interest rate period, for the respective interest rate period determined at our option, payable in arrears upon cessation of the interest rate period elected, provided that for an interest rate period longer than three months, payable in arrears on the respective dates that fall every three months from the beginning of such interest rate period. |
At March 31, 2015 , we had $ 50.0 million of borrowings outstanding of which $34.0 million was accruing interest at a rate of 2.4245% and $16.0 million was accruing interest at a rate of 2.4275% .
We were in compliance with all financial debt covenants for all periods presented.
2012 Indenture. Our 2012 Notes are guaranteed, jointly and severally, on a second priority senior secured basis, by Surgical Services, and are also similarly guaranteed by certain of our future 100%-owned domestic subsidiaries. The
12
2012 Notes are our second priority senior secured obligations and rank (i) equal in right of payment with all of our existing and future unsubordinated indebtedness, and effectively senior to any such unsecured indebtedness to the extent of the value of collateral; (ii) senior in right of payment to all of our and our guarantors’ existing and future subordinated indebtedness; (iii) effectively junior to our senior secured credit facility; and (iv) structurally subordinated to any indebtedness and other liabilities (including trade payables) of any of our future subsidiaries that are not guarantors.
The 2012 Indenture governing the 2012 Notes contains covenants that limit our and our guarantors’ ability, subject to certain definitions and exceptions, and certain of our future subsidiaries’ ability to:
|
· |
|
incur additional indebtedness; |
|
· |
|
pay cash dividends or distributions on our capital stock or repurchase our capital stock or subordinated debt; |
|
· |
|
issue redeemable stock or preferred stock; |
|
· |
|
issue stock of subsidiaries; |
|
· |
|
make certain investments; |
|
· |
|
transfer or sell assets; |
|
· |
|
create liens on our assets to secure debt; |
|
· |
|
enter into transactions with affiliates; and |
|
· |
|
merge or consolidate with another company. |
The 2012 Indenture specifies certain events of default, including among others, failure to pay principal, interest or premium, violation of covenants and agreements, cross-defaults to other material agreements, bankruptcy events, invalidity of guarantees, and a default in the performance by us of the security documents relating to the 2012 Indenture. Some events of default will be triggered only after certain grace or cure periods have expired, or provide for materiality thresholds. In the event certain bankruptcy-related defaults occur, the 2012 Notes will become due and payable immediately. If any other default occurs, the Trustee (and in some cases the noteholders) would be entitled to take various actions, including acceleration of amounts due under the 2012 Indenture.
We were in compliance with all financial debt covenants for all periods presented.
9. Commitments and Contingencies
The Company, in the ordinary course of business, could be subject to liability claims related to employees and the equipment that it rents and services. Asserted claims are subject to many uncertainties and the outcome of individual matters is not predictable. While the ultimate resolution of these actions may have an impact on the Company’s financial results for a particular reporting period, management believes that any such resolution would not have a material adverse effect on the financial position, results of operations or cash flows of the Company and the chance of a negative outcome on outstanding litigation is considered remote.
In 2014, a supplier ceased distribution of one of their product s in the United States following a request fro m the FDA. As of March 31, 2015 , the Company had approximately $4 million of equipment from this supplier, which it believes is recoverable, offs et with $3 million of a payable to this supplier . See Note 17 Subsequent Event.
The Company was notified in 2014 that a national group purchasing organization awarded a sole source agreement to a competitor under agreements that expired on December 31, 2014.
On January 13, 2015, the Company filed suit in the Western District of Texas against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc. and Hill-Rom Services, Inc. (the "Defendants") alleging that the Defendants violated federal and state antitrust laws by willfully and unlawfully engaging in a pattern of exclusionary and predatory conduct in order to foreclose market competition and seeking actual damages, trebled damages and punitive damages. At this early stage in the litigation, the Company does not believe the expense of litigation will have a material impact on the Company's operating expenses or financial results.
13
10. Related Party Transactions
Management Agreement
On May 31, 2007, we and Irving Place Capital Merchant Manager III, L.P. (“IPC”) entered into a professional services agreement pursuant to which IPC provides general advisory and management services to us with respect to financial and operating matters. IPC is a principal owner of Parent, and the following members of our board of directors are associated with IPC: Michael Feiner, Robert Juneja, and Bret Bowerman. The professional services agreement requires us to pay an annual fee for ongoing advisory and management services equal to the greater of $0.5 million or 0.75% of our Adjusted EBITDA (as defined in the professional services agreement) for the immediately preceding fiscal year, payable in quarterly installments. The professional services agreement provides that IPC will be reimbursed for its reasonable out-of-pocket expenses in connection with certain activities undertaken pursuant to the professional services agreement and will be indemnified for liabilities incurred in connection with its role under the professional services agreement, other than for liabilities resulting from its gross negligence or willful misconduct. The term of the professional services agreement commenced on May 31, 2007 and will remain in effect unless and until either party notifies the other of its desire to terminate, we are sold to a third-party purchaser or we consummate a qualified initial public offering, as defined in the professional services agreement. Total professional services fees incurred to IPC were $0.2 and $0.3 million for the three month periods ended March 31, 2015 and 2014 , respectively.
In the ordinary course of business, we entered into engagement letters with CTPartners, LLC (“CTPartners”) to conduct searches for certain executive positions. One member of our board of directors is also a director of CTPartners. Total fees incurred to CTPartners was $0.02 and $0 million for the three month periods ended March 31, 2015 and 2014 , respectively .
The Company believes that the aforementioned arrangements and relationships were provided in the ordinary course of business.
11. Limited Liability Companies
We participate with others in the formation of LLCs in which Surgical Services becomes a partner and shares the financial interest with the other investors. Surgical Services is the primary beneficiary of these LLCs. These LLCs acquire certain medical equipment for use in their respective business activities, which generally focus on surgical procedures. The LLCs will acquire medical equipment for rental purposes under equipment financing leases. At March 31, 2015 , the LLCs had approximately $0.5 million of total assets. The third party investors in each respective LLC generally provide the lease financing company with individual proportionate lease guarantees based on their respective ownership percentages in the LLCs. In addition, Surgical Services will provide such financing companies with its corporate guarantee based on its respective ownership interest in each LLC. In certain instances, Surgical Services has provided such financing companies with an overall corporate guarantee in connection with equipment financing transactions. In such instances, the individual investors in each respective LLC will generally indemnify us against losses, if any, incurred in connection with its corporate guarantee. Additionally, we provide operational and administrative support to the LLCs in which it is a partner. As of March 31, 2015 , we held interests in six active LLCs.
In accordance with guidance issued by the FASB, we account for equity investments in LLCs (in which we are the primary beneficiary) under the full consolidation method whereby transactions between Surgical Services and the LLCs have been eliminated through consolidation.
14
12. Segment Information
Our reporting segments consist of Medical Equipment Solutions (“MES”), Clinical Engineering Solutions (“CES”) and Surgical Services (“SS”). Certain operating information for our segments as well as a reconciliation of total Company gross margin to loss before income taxes and noncontrolling interest was as follows:
Medical Equipment Solutions
(in thousands)
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
||||
|
|
March 31, |
|
||||
|
|
2015 |
|
2014 |
|
||
Revenues |
|
$ |
|
|
$ |
|
|
Cost of revenue |
|
|
|
|
|
|
|
Medical equipment depreciation |
|
|
|
|
|
|
|
Gross margin |
|
$ |
|
|
$ |
|
|
Clinical Engineering Solutions
(in thousands)
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
||||
|
|
March 31, |
|
||||
|
|
2015 |
|
2014 |
|
||
Revenues |
|
$ |
|
|
$ |
|
|
Cost of revenue |
|
|
|
|
|
|
|
Gross margin |
|
$ |
|
|
$ |
|
|
Surgical Services
(in thousands)
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
||||
|
|
March 31, |
|
||||
|
|
2015 |
|
2014 |
|
||
Revenues |
|
$ |
|
|
$ |
|
|
Cost of revenue |
|
|
|
|
|
|
|
Medical equipment depreciation |
|
|
|
|
|
|
|
Gross margin |
|
$ |
|
|
$ |
|
|
Total Gross Margin and Reconciliation to Loss Before Income Taxes and Noncontrolling Interest
(in thousands)
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
||||
|
|
March 31, |
|
||||
|
|
2015 |
|
2014 |
|
||
Total gross margin |
|
$ |
|
|
$ |
|
|
Selling, general and administrative |
|
|
|
|
|
|
|
Restructuring, acquisition and integration expenses |
|
|
— |
|
|
|
|
Interest expense |
|
|
|
|
|
|
|
Loss before income taxes and noncontrolling interest |
|
$ |
|
|
$ |
|
|
15
Total Assets By Reporting Segment
(in thousands)
|
|
|
|
|
|
|
|
|
|
March 31, |
|
December 31, |
|
||
|
|
2015 |
|
2014 |
|
||
Medical Equipment Solutions |
|
$ |
|
|
$ |
|
|
Clinical Engineering Solutions |
|
|
|
|
|
|
|
Surgical Services |
|
|
|
|
|
|
|
Total Company Assets |
|
$ |
|
|
$ |
|
|
The following table provides additional detail on percentage of revenue for each group of similar products sold or services provided in the MES, CES and SS segments:
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
||
|
|
March 31, |
|
|
||
|
|
2015 |
|
2014 |
|
|
MES |
|
|
|
|
|
|
Equipment usage solutions |
|
|
% |
|
% |
|
Equipment/disposable sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
CES |
|
|
|
|
|
|
Service solutions |
|
|
|
|
|
|
SS |
|
|
|
|
|
|
Equipment usage solutions |
|
|
|
|
|
|
Equipment/disposable sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
% |
|
% |
|
13. Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We evaluate the recoverability of our deferred tax assets by scheduling the expected reversals of deferred tax assets and liabilities in order to determine whether net operating loss carry forwards are recoverable prior to expiration and have established a valuation allowance in accordance with ASC Topic 740 , “Income Taxes” . The tax expense for the three months ended March 31, 2015 primarily relates to state minimum fees. The expected tax benefit from operating loss during the three months ended March 31, 2015 was offset by the recording of additional valuation allowance. In future reporting periods, we will continue to assess the likelihood that deferred tax assets will be realizable.
At March 31, 2015 , the Company had available unused federal net operating loss carryforwards of approximately $2 19. 8 million. The net operating loss carryforwards will expire at various dates from 2017 through 2035.
14. Consolidating Financial Statements
In accordance with the provisions of the 2012 Indenture, as a 100% -owned subsidiary of UHS, Surgical Services has jointly and severally guaranteed all the Company’s Obligations (as defined in the 2012 Indenture) on a full and unconditional basis. Consolidating financial information of UHS and the guarantor is presented on the following pages.
16
Universal Hospital Services, Inc.
Consolidating Balance Sheets
(in thousands, except share and per share information)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2015 |
||||||||||
|
|
Parent |
|
Subsidiary |
|
|
|
|
|
|||
|
|
Issuer |
|
Guarantor |
|
Consolidating |
|
|
|
|||
|
|
UHS |
|
Surgical Services |
|
Adjustments |
|
Consolidated |
||||
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable, less allowance for doubtful accounts |
|
$ |
|
|
$ |
|
|
$ |
— |
|
$ |
|
Due from affiliates |
|
|
|
|
|
— |
|
|
|
|
|
— |
Inventories |
|
|
|
|
|
|
|
|
— |
|
|
|
Deferred income taxes, net |
|
|
— |
|
|
|
|
|
— |
|
|
|
Other current assets |
|
|
|
|
|
|
|
|
— |
|
|
|
Total current assets |
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment: |
|
|
|
|
|
|
|
|
|
|
|
|
Medical equipment |
|
|
|
|
|
|
|
|
— |
|
|
|
Property and office equipment |
|
|
|
|
|
|
|
|
— |
|
|
|
Accumulated depreciation |
|
|
|
|
|
|
|
|
— |
|
|
|
Total property and equipment, net |
|
|
|
|
|
|
|
|
— |
|
|
|
Other long-term assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
|
|
|
|
|
|
— |
|
|
|
Investment in subsidiary |
|
|
|
|
|
— |
|
|
|
|
|
— |
Other intangibles, net |
|
|
|
|
|
|
|
|
— |
|
|
|
Other, primarily deferred financing costs, net |
|
|
|
|
|
|
|
|
— |
|
|
|
Total assets |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Liabilities and (Deficit) Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Current portion of long-term debt |
|
$ |
|
|
$ |
|
|
$ |
— |
|
$ |
|
Book overdrafts |
|
|
|
|
|
|
|
|
— |
|
|
|
Due to affiliates |
|
|
— |
|
|
|
|
|
|
|
|
— |
Accounts payable |
|
|
|
|
|
|
|
|
— |
|
|
|
Accrued compensation |
|
|
|
|
|
|
|
|
— |
|
|
|
Accrued interest |
|
|
|
|
|
— |
|
|
— |
|
|
|
Dividend payable |
|
|
|
|
|
— |
|
|
— |
|
|
|
Other accrued expenses |
|
|
|
|
|
|
|
|
— |
|
|
|
Total current liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt, less current portion |
|
|
|
|
|
|
|
|
— |
|
|
|
Pension and other long-term liabilities |
|
|
|
|
|
— |
|
|
— |
|
|
|
Payable to Parent |
|
|
|
|
|
— |
|
|
— |
|
|
|
Deferred income taxes, net |
|
|
|
|
|
|
|
|
— |
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
(Deficit) Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Common stock |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Additional paid-in capital |
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated deficit |
|
|
|
|
|
|
|
|
— |
|
|
|
Accumulated loss in subsidiary |
|
|
|
|
|
— |
|
|
|
|
|
— |
Accumulated other comprehensive loss |
|
|
|
|
|
— |
|
|
— |
|
|
|
Total Universal Hospital Services, Inc. (deficit) equity |
|
|
|
|
|
|
|
|
|
|
|
|
Noncontrolling interest |
|
|
— |
|
|
|
|
|
— |
|
|
|
Total (deficit) equity |
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and (deficit) equity |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
17
Universal Hospital Services, Inc.
Consolidating Balance Sheets
(in thousands, except share and per share information)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2014 |
||||||||||
|
|
Parent |
|
Subsidiary |
|
|
|
|
|
|||
|
|
Issuer |
|
Guarantor |
|
Consolidating |
|
|
|
|||
|
|
UHS |
|
Surgical Services |
|
Adjustments |
|
Consolidated |
||||
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable, less allowance for doubtful accounts |
|
$ |
|
|
$ |
|
|
$ |
— |
|
$ |
|
Due from affiliates |
|
|
|
|
|
— |
|
|
|
|
|
— |
Inventories |
|
|
|
|
|
|
|
|
— |
|
|
|
Deferred income taxes, net |
|
|
— |
|
|
|
|
|
— |
|
|
|
Other current assets |
|
|
|
|
|
|
|
|
— |
|
|
|
Total current assets |
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment: |
|
|
|
|
|
|
|
|
|
|
|
|
Medical equipment |
|
|
|
|
|
|
|
|
— |
|
|
|
Property and office equipment |
|
|
|
|
|
|
|
|
— |
|
|
|
Accumulated depreciation |
|
|
|
|
|
|
|
|
— |
|
|
|
Total property and equipment, net |
|
|
|
|
|
|
|
|
— |
|
|
|
Other long-term assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
|
|
|
|
|
|
— |
|
|
|
Investment in subsidiary |
|
|
|
|
|
— |
|
|
|
|
|
— |
Other intangibles, net |
|
|
|
|
|
|
|
|
— |
|
|
|
Other, primarily deferred financing costs, net |
|
|
|
|
|
|
|
|
— |
|
|
|
Total assets |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Liabilities and (Deficit) Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Current portion of long-term debt |
|
$ |
|
|
$ |
|
|
$ |
— |
|
$ |
|
Book overdrafts |
|
|
|
|
|
|
|
|
— |
|
|
|
Due to affiliates |
|
|
— |
|
|
|
|
|
|
|
|
— |
Accounts payable |
|
|
|
|
|
|
|
|
— |
|
|
|
Accrued compensation |
|
|
|
|
|
|
|
|
— |
|
|
|
Accrued interest |
|
|
|
|
|
— |
|
|
— |
|
|
|
Dividend payable |
|
|
|
|
|
— |
|
|
— |
|
|
|
Other accrued expenses |
|
|
|
|
|
|
|
|
— |
|
|
|
Total current liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt, less current portion |
|
|
|
|
|
|
|
|
— |
|
|
|
Pension and other long-term liabilities |
|
|
|
|
|
— |
|
|
— |
|
|
|
Payable to Parent |
|
|
|
|
|
— |
|
|
— |
|
|
|
Deferred income taxes, net |
|
|
|
|
|
|
|
|
— |
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
(Deficit) Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Common stock |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Additional paid-in capital |
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated deficit |
|
|
|
|
|
|
|
|
— |
|
|
|
Accumulated loss in subsidiary |
|
|
|
|
|
— |
|
|
|
|
|
— |
Accumulated other comprehensive loss |
|
|
|
|
|
— |
|
|
— |
|
|
|
Total Universal Hospital Services, Inc. (deficit) equity |
|
|
|
|
|
|
|
|
|
|
|
|
Noncontrolling interest |
|
|
— |
|
|
|
|
|
— |
|
|
|
Total (deficit) equity |
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and (deficit) equity |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
18
Universal Hospital Services, Inc.
Consolidating Statements of Operations
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2015 |
||||||||||
|
|
Parent |
|
Subsidiary |
|
|
|
|
|
|||
|
|
Issuer |
|
Guarantor |
|
Consolidating |
|
|
|
|||
|
|
UHS |
|
Surgical Services |
|
Adjustments |
|
Consolidated |
||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Medical equipment solutions |
|
$ |
|
|
$ |
— |
|
$ |
— |
|
$ |
|
Clinical engineering solutions |
|
|
|
|
|
— |
|
|
— |
|
|
|
Surgical services |
|
|
— |
|
|
|
|
|
— |
|
|
|
Total revenues |
|
|
|
|
|
|
|
|
— |
|
|
|
Cost of Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of medical equipment solutions |
|
|
|
|
|
— |
|
|
— |
|
|
|
Cost of clinical engineering solutions |
|
|
|
|
|
— |
|
|
— |
|
|
|
Cost of surgical services |
|
|
— |
|
|
|
|
|
— |
|
|
|
Medical equipment depreciation |
|
|
|
|
|
|
|
|
— |
|
|
|
Total costs of revenues |
|
|
|
|
|
|
|
|
— |
|
|
|
Gross margin |
|
|
|
|
|
|
|
|
— |
|
|
|
Selling, general and administrative |
|
|
|
|
|
|
|
|
— |
|
|
|
Operating income |
|
|
|
|
|
|
|
|
— |
|
|
|
Equity in earnings of subsidiary |
|
|
|
|
|
— |
|
|
|
|
|
— |
Interest expense |
|
|
|
|
|
|
|
|
— |
|
|
|
(Loss) income before income taxes and noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
|
|
|
|
|
|
|
— |
|
|
|
Consolidated net (loss) income |
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to noncontrolling interest |
|
|
— |
|
|
|
|
|
— |
|
|
|
Net (loss) income attributable to Universal Hospital Services, Inc. |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
19
Universal Hospital Services, Inc.
Consolidating Statements of Operations
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2014 |
||||||||||
|
|
Parent |
|
Subsidiary |
|
|
|
|
|
|||
|
|
Issuer |
|
Guarantor |
|
Consolidating |
|
|
|
|||
|
|
UHS |
|
Surgical Services |
|
Adjustments |
|
Consolidated |
||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Medical equipment solutions |
|
$ |
|
|
$ |
— |
|
$ |
— |
|
$ |
|
Clinical engineering solutions |
|
|
|
|
|
— |
|
|
— |
|
|
|
Surgical services |
|
|
— |
|
|
|
|
|
— |
|
|
|
Total revenues |
|
|
|
|
|
|
|
|
— |
|
|
|
Cost of Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of medical equipment solutions |
|
|
|
|
|
— |
|
|
— |
|
|
|
Cost of clinical engineering solutions |
|
|
|
|
|
— |
|
|
— |
|
|
|
Cost of surgical services |
|
|
— |
|
|
|
|
|
— |
|
|
|
Medical equipment depreciation |
|
|
|
|
|
|
|
|
— |
|
|
|
Total costs of revenues |
|
|
|
|
|
|
|
|
— |
|
|
|
Gross margin |
|
|
|
|
|
|
|
|
— |
|
|
|
Selling, general and administrative |
|
|
|
|
|
|
|
|
— |
|
|
|
Restructuring, acquisition and integration expenses |
|
|
|
|
|
— |
|
|
— |
|
|
|
Operating income (loss) |
|
|
|
|
|
|
|
|
— |
|
|
|
Equity in loss of subsidiary |
|
|
|
|
|
— |
|
|
|
|
|
— |
Interest expense |
|
|
|
|
|
|
|
|
— |
|
|
|
Loss before income taxes and noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
Provision (benefit) for income taxes |
|
|
|
|
|
|
|
|
— |
|
|
|
Consolidated net loss |
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to noncontrolling interest |
|
|
— |
|
|
|
|
|
— |
|
|
|
Net loss attributable to Universal Hospital Services, Inc. |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
20
Universal Hospital Services, Inc.
Consolidating Statements of Comprehensive Loss
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2015 |
|
||||||||||
|
|
Parent |
|
Subsidiary |
|
|
|
|
|
|
|||
|
|
Issuer |
|
Guarantor |
|
Consolidating |
|
|
|
|
|||
|
|
UHS |
|
Surgical Services |
|
Adjustments |
|
Consolidated |
|
||||
Consolidated net (loss) income |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
Total other comprehensive income |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Comprehensive (loss) income |
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income attributable to noncontrolling interest |
|
|
— |
|
|
|
|
|
— |
|
|
|
|
Comprehensive (loss) income attributable to Universal Hospital Services, Inc. |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2014 |
|
||||||||||
|
|
Parent |
|
Subsidiary |
|
|
|
|
|
|
|||
|
|
Issuer |
|
Guarantor |
|
Consolidating |
|
|
|
|
|||
|
|
UHS |
|
Surgical Services |
|
Adjustments |
|
Consolidated |
|
||||
Consolidated net loss |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
Total other comprehensive income |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income attributable to noncontrolling interest |
|
|
— |
|
|
|
|
|
— |
|
|
|
|
Comprehensive loss attributable to Universal Hospital Services, Inc. |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
21
Universal Hospital Services, Inc.
Consolidating Statements of Cash Flows
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2015 |
||||||||||
|
|
Parent |
|
Subsidiary |
|
|
|
|
|
|||
|
|
Issuer |
|
Guarantor |
|
Consolidating |
|
|
|
|||
|
|
UHS |
|
Surgical Services |
|
Adjustments |
|
Consolidated |
||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net (loss) income |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Adjustments to reconcile net (loss) income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
|
|
|
|
|
|
|
— |
|
|
|
Assets impairment charges |
|
|
|
|
|
— |
|
|
— |
|
|
|
Amortization of intangibles, deferred financing costs and bond premium |
|
|
|
|
|
|
|
|
— |
|
|
|
Equity in earnings of subsidiary |
|
|
|
|
|
— |
|
|
|
|
|
— |
Provision for doubtful accounts |
|
|
|
|
|
|
|
|
— |
|
|
|
Provision for inventory obsolescence |
|
|
|
|
|
|
|
|
— |
|
|
|
Non-cash share-based compensation expense |
|
|
|
|
|
— |
|
|
— |
|
|
|
Gain on sales and disposals of equipment |
|
|
|
|
|
|
|
|
— |
|
|
|
Deferred income taxes |
|
|
|
|
|
|
|
|
— |
|
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
|
|
|
|
— |
|
|
|
Due from (to) affiliates |
|
|
|
|
|
|
|
|
— |
|
|
— |
Inventories |
|
|
|
|
|
|
|
|
— |
|
|
|
Other operating assets |
|
|
|
|
|
|
|
|
— |
|
|
|
Accounts payable |
|
|
|
|
|
|
|
|
— |
|
|
|
Other operating liabilities |
|
|
|
|
|
|
|
|
— |
|
|
|
Net cash provided by operating activities |
|
|
|
|
|
|
|
|
— |
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Medical equipment purchases |
|
|
|
|
|
|
|
|
— |
|
|
|
Property and office equipment purchases |
|
|
|
|
|
|
|
|
— |
|
|
|
Proceeds from disposition of property and equipment |
|
|
|
|
|
|
|
|
— |
|
|
|
Net cash used in investing activities |
|
|
|
|
|
|
|
|
— |
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds under senior secured credit facility |
|
|
|
|
|
— |
|
|
— |
|
|
|
Payments under senior secured credit facility |
|
|
|
|
|
— |
|
|
— |
|
|
|
Payments of principal under capital lease obligations |
|
|
|
|
|
|
|
|
— |
|
|
|
Distributions to noncontrolling interests |
|
|
— |
|
|
|
|
|
— |
|
|
|
Dividend and equity distribution payments |
|
|
|
|
|
— |
|
|
— |
|
|
|
Change in book overdrafts |
|
|
|
|
|
|
|
|
— |
|
|
|
Net cash provided by (used in) financing activities |
|
|
|
|
|
|
|
|
— |
|
|
|
Net change in cash and cash equivalents |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Cash and cash equivalents at the beginning of period |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Cash and cash equivalents at the end of period |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
22
Universal Hospital Services, Inc.
Consolidating Statements of Cash Flows
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2014 |
||||||||||
|
|
Parent |
|
Subsidiary |
|
|
|
|
|
|||
|
|
Issuer |
|
Guarantor |
|
Consolidating |
|
|
|
|||
|
|
UHS |
|
Surgical Services |
|
Adjustments |
|
Consolidated |
||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net loss |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
|
|
|
|
|
|
|
— |
|
|
|
Assets impairment charge |
|
|
|
|
|
— |
|
|
— |
|
|
|
Amortization of intangibles, deferred financing costs and bond premium |
|
|
|
|
|
|
|
|
— |
|
|
|
Equity in loss of subsidiary |
|
|
|
|
|
— |
|
|
|
|
|
— |
Provision for doubtful accounts |
|
|
|
|
|
|
|
|
— |
|
|
|
Provision for inventory obsolescence |
|
|
|
|
|
|
|
|
— |
|
|
|
Non-cash share-based compensation expense |
|
|
|
|
|
|
|
|
— |
|
|
|
Gain on sales and disposals of equipment |
|
|
|
|
|
|
|
|
— |
|
|
|
Deferred income taxes |
|
|
|
|
|
|
|
|
— |
|
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
|
|
|
|
— |
|
|
|
Due from (to) affiliates |
|
|
|
|
|
|
|
|
— |
|
|
— |
Inventories |
|
|
|
|
|
|
|
|
— |
|
|
|
Other operating assets |
|
|
|
|
|
|
|
|
— |
|
|
|
Accounts payable |
|
|
|
|
|
|
|
|
— |
|
|
|
Other operating liabilities |
|
|
|
|
|
|
|
|
— |
|
|
|
Net cash provided by operating activities |
|
|
|
|
|
|
|
|
— |
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Medical equipment purchases |
|
|
|
|
|
|
|
|
— |
|
|
|
Property and office equipment purchases |
|
|
|
|
|
|
|
|
— |
|
|
|
Proceeds from disposition of property and equipment |
|
|
|
|
|
— |
|
|
— |
|
|
|
Net cash used in investing activities |
|
|
|
|
|
|
|
|
— |
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds under senior secured credit facility |
|
|
|
|
|
— |
|
|
— |
|
|
|
Payments under senior secured credit facility |
|
|
|
|
|
— |
|
|
— |
|
|
|
Payments of principal under capital lease obligations |
|
|
|
|
|
|
|
|
— |
|
|
|
Distributions to noncontrolling interests |
|
|
— |
|
|
|
|
|
— |
|
|
|
Dividend and equity distribution payments |
|
|
|
|
|
— |
|
|
— |
|
|
|
Change in book overdrafts |
|
|
|
|
|
|
|
|
— |
|
|
|
Net cash provided by (used in) financing activities |
|
|
|
|
|
|
|
|
— |
|
|
|
Net change in cash and cash equivalents |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Cash and cash equivalents at the beginning of period |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Cash and cash equivalents at the end of period |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
23
15. Restructuring
We incurred restructuring expense of $0 and $1.3 million during the three months ended March 31, 2015 and 2014 , respectively, the majority of which related to severances and other related expenses. The restructuring expense impact was recorded under the Corporate and Unallocated segment. As of December 31, 2014 , we had $1.6 million of restructuring liability. For the three months ended March 31, 2015 , $0.4 million in restructuring charges was paid. No additional restructuring was recorded in the first quarter of 2015 for new severance arrangements and the remaining liability of $1.2 million as of March 31, 2015 is expected to be paid out by the end of the first quarter of 2016 and is included in the Other accrued expenses in the Consolidated Balance Sheets. As of December 31, 2 013 , we had $0.3 million of restructuring liability. For the three months ended March 31, 2014 , we incurred restructuring expense of $1.3 million and $0.2 million in restructuring charges was paid and the remaining $1.4 was a liability as of March 31, 2014 .
16. Concentration
One customer accounted for approximately 14% of total revenue for the three months ended March 31, 2015 and 2014 .
17. Subsequent Event
On May 7 , 2015, the Company entered into an agreement , with one of its former suppliers, resolving all matters related to the cessation of our commercial relationships with each other . The Company expects to receive a pproximately $7 million in net cash after settling all open receivables and payables between the two parties and return of relevant product .
24
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following should be read in conjunction with the accompanying consolidated financial statements and notes.
BUSINESS OVERVIEW
Our Company
Universal Hospital Services, Inc. (“we”, “our”, “us”, the “Company”, or “UHS”) is a leading nationwide provider of health care technology management and service solutions to the United States health care industry. We provide our customers comprehensive health care technology management, service and clinical solutions that we believe help reduce capital and operating expenses, increase medical equipment and staff productivity , and support improved patient safety and outcomes.
We commenced operations in 1939, originally incorporated in Minnesota in 1954 and reincorporated in Delaware in 2001. All of our outstanding capital stock is owned by UHS Holdco, Inc. (“Parent”), which acquired the Company in a recapitalization in May 2007. Parent is owned by affiliates of Irving Place Capital Merchant Manager III, L.P. (“IPC”) and certain current and former members of our management .
UHS delivers health care solutions through three segments: Medical Equipment Solutions (“MES”), Clinical Engineering Solutions (“CES”) and S urgical Services (“SS”). As of March 31, 2015 , we owned or managed over 700,000 units of medical equipment consisting of approximately 400,000 owned or managed units in our MES segment, over 300,000 units of customer-owned equipment we managed in our CES segment and over 5,000 units of owned or managed mobile surgical equipment in our SS segment. Our diverse customer base includes more than 7,000 national, regional and local acute care hospitals and alternate site providers (such as long-term acute care hospitals, skilled nursing facilities, surgery centers, specialty hospitals, nursing homes and home care providers). We also have relationships with more than 200 medical device manufacturers, many of the nation’s largest group purchasing organizations (“GPOs”) and many health system integrated delivery networks (“IDNs”). All of our solutions leverage our nationwide network of 83 district service centers, five CES Centers of Excellence and an additional five stand-alone SS service centers, together with our more than 75 years of experience managing and servicing all aspects of medical equipment. Our fees are paid directly by our customers rather than by direct reimbursement from third-party payors, such as private insurers, Medicare or Medicaid.
We report our financial results in three segments. Our reporting segments consist of MES, CES and SS . We evaluate the performance of our reportable segments based on gross margin. The accounting policies of the individual reportable segments are the same as those of the entire company.
In 2014, a supplier ceased distribution of one of their product s in the United States following a request from the FDA. As of March 31, 2015 , the Company had approximately $4 million of equipment from this supplier, which it believes is recoverable, offset with $3 million of a payable to this supplier . The net loss in revenue in the first quarter was approximately $4 million and the total impact in 2015 is estimated at approximately $8 to $10 million. The cash impact to gross margin in the first quarter was approximately $1.5 million and the total impact in 2015 is estimated at approximately $3 to $4 million.
On May 7 , 2015, the Company entered into an agreement , with this supplier, resolving all matters related to the cessation of our commercial relationships with each other . The Company expects to receive approximately $7 million in net cash after settling all open receivables and payables between the two parties and return of relevant product.
The Company was notified in 2014 that a national group purchasing organization awarded a sole source agreement to a competitor under agreements that expired on December 31, 2014. The loss in revenue was approximately $2 million in the first quarter and the total impact in 2015 is e stimated at $10 to $15 million. The Company had previously estimated the loss in revenue for 2015 at $15 to $20 million. The transition of the customers is difficult to predict and has been slower than previously forecasted. The gross margin impact, while difficult to estimate given the fixed nature of the expense base, is approximately $1.5 million in the first quarter and the total impact in 2015 is estimated at approximately $7 to $11 million.
25
Medical Equipment Solutions
Our MES segment accounted for $74.1 and $76.7 million, or approximately 65.3% and 67.7% of our revenues, for the three months ended March 31, 2015 and 2014 , respectively. As of March 31, 2015 , the MES segment owned or managed approximately 400,000 units of medical equipment ranging across many clinical categories, manufacturers and models. These solutions are provided primarily to hospitals and other acute care providers for use through their facilities, including the emergency room, operating room, critical care, intensive care, rehabilitation and general patient care areas.
Our MES segment started more than 75 years ago as our leading medical equipment peak needs usage business and has transformed into providing comprehensive outsourced and on-site solutions that manage all aspects of medical equipment in a health care facility. We currently provide MES solutions to more than 7,000 acute care hospitals and alternate site providers in the United States, including some of the nation’s premier health care institutions. We expect much of our future growth in this segment to be driven by our customers outsourcing more of their medical equipment needs and taking full advantage of our diversified product offering, clinical education and support, customized agreements and 360 On-site Managed Solutions.
We have four primary solutions in our MES segment:
|
· |
|
Supplemental and Peak Needs Usage Solutions; |
|
· |
|
Customized Equipment Agreements Solutions; |
|
· |
|
360 On-site Managed Solutions; and |
|
· |
|
Specialty Medical Equipment Sales, Distribution and Disposal Solutions. |
Clinical Engineering Solutions
Our CES segment accounted for $24.4 and $22.7 million, or approximately 21.5% and 20.0% of our revenues, for the three months ended March 31, 2015 and 2014 , respectively. We offer a broad range of inspection, preventive maintenance, repair, logistic and consulting services through our team of over 370 technicians and professionals located throughout the United States in our nationwide network of service centers. We managed over 300,000 units of customer owned equipment as of March 31, 2015 . In addition, as of March 31, 2015 , we serviced approximately 400,000 units that we own or directly manage in our MES segment .
Our CES segment leverages our over 75 years of experience and our extensive equipment database in repairing and maintaining a broad range of health care technologies. Historically, we have been our own largest customer for CES services in order to repair and maintain approximately 400,000 units that we own or directly manage. However, we believe our CES segment has significant future growth potential by offering non-capital based comprehensive solutions as a stand-alone or complementary alternative for customers that own medical equipment but lack the infrastructure, expertise, or scale to perform routine maintenance, repair, record keeping, and lifecycle analysis and planning functions. We also believe hospital and other facility-based clients will face increasing challenges in managing sophisticated medical equipment that requires connectivity and interoperability with information technology systems, compliance with the 10 th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), regulatory requirements, integration with EMR, maintenance and management of software databases and management of other medical equipment patient information and safety features.
We have three primary solutions in our CES segment:
|
· |
|
Supplemental Maintenance and Repair Solutions; |
|
· |
|
360 On-site Managed Solutions; and |
|
· |
|
Health Care Technology Advisory Solutions. |
Surgical Services
Our SS segment accounted for $15.0 and $13.9 million, or approximately 13.2% and 12.3% of our revenues, for the three months ended March 31, 2015 and 2014 , respectively. As of March 31, 2015 , we owned or managed over 5,000 units of mobile surgical equipment in our SS segment, primarily used in the practice of general surgery, orthopedic surgery, otolaryngology, urology, obstetrics, gynecology, podiatry, dermatology and plastic/cosmetics.
26
SS provides high end, state-of-the-art surgical equipment and associated products along with trained and certified Surgical Equipment Technologists (“technologists”) to assist in the procedural operation of the equipment. We provide these services to over 1,000 acute care hospitals and surgery centers through our nationwide network of 83 district service centers and an additional five stand-alone SS service centers. Our technologists work in the operating room (“O.R.”) and support physicians and O.R. personnel. The services are offered on a per-procedure basis. Our technologists deliver, set up, and create a safe environment for hospital and clinical personnel operating the equipment and provide all necessary disposable materials needed. Our technologists work closely with our customers to confirm that all certifications and credentials meet requirements to provide on-site services. Our technologists also assist customers in the operation of facility-owned assets and supplement the training and staffing of their personnel. As of March 31, 2015 , SS provided solutions in 4 2 states.
We have two primary solutions in our SS segment:
|
· |
|
On-Demand and Scheduled Usage Solutions; and |
|
· |
|
360 On-site Managed Solutions. |
RESULTS OF OPERATIONS
The following discussion addresses:
|
· |
|
our financial condition as of March 31, 2015 and |
|
· |
|
the results of operations for the three-month periods ended March 31, 2015 and 2014 . |
This discussion should be read in conjunction with the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q and the Management’s Discussion and Analysis of Financial Condition and Results of Operations section included in our 2014 Annual Report on Form 10-K, filed with the Securities and Exchange Commission.
The following table provides information on the percentages of certain items of selected financial data compared to total revenues for the three-month periods ended March 31, 2015 and 2014 . The table below also indicates the percentage increase or decrease over the prior comparable period.
|
|
|
|
|
|
|
|
|
|
Percent to Total Revenues |
|
Percent |
|
||
|
|
Three Months Ended March 31, |
|
Increase |
|
||
|
|
2015 |
|
2014 |
|
(Decrease) |
|
Revenue |
|
|
|
|
|
|
|
Medical equipment solutions |
|
|
% |
|
% |
|
% |
Clinical engineering solutions |
|
|
|
|
|
|
|
Surgical services |
|
|
|
|
|
|
|
Total revenues |
|
|
% |
|
% |
|
|
Cost of Revenue |
|
|
|
|
|
|
|
Cost of medical equipment solutions |
|
|
|
|
|
|
|
Cost of clinical engineering solutions |
|
|
|
|
|
|
|
Cost of surgical services |
|
|
|
|
|
|
|
Medical equipment depreciation |
|
|
|
|
|
|
|
Total costs of revenues |
|
|
|
|
|
|
|
Gross margin |
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
|
|
|
|
|
Restructuring, acquisition and integration expenses |
|
— |
|
|
|
* |
|
Operating income |
|
|
|
|
|
|
|
Interest expense |
|
|
|
|
|
|
|
Loss before income taxes and noncontrolling interest |
|
|
|
|
|
|
|
Provision for income taxes |
|
|
|
|
|
|
|
Consolidated net loss |
|
|
% |
|
% |
|
|
27
*Not meaningful
Consolidated Results of Operations for the three months ended March 31, 2015 compared to the three months ended March 31, 2014
Total Revenue
Total revenue for the three months ended March 31, 2015 was $113.5 million, compared to $113.3 million for the three months ended March 31, 2014 , an increase of $0.2 million or 0.1% . The net increase was primarily due to additional revenue in our MES segment related to growth in our 360 On-site Managed Sol utions (“360 s olutions”) of $2.6 million , g rowth in our CES segment of $1.7 million related to growth in our 360 solutions and organic growth in our SS segment of $1.0 million . These increases were partially offset by the decline in NPWT device rental and disposable sales of $4.0 million due to the interruption of Smith & Nephew commercial distribution of the RENASYS product line and $2.1 million due to the beginning of customer transitions from the loss of the national GPO contract.
Cost of Revenue
Total cost of revenue for the three months ended March 31, 2015 was $76.8 million compared to $78.7 million for the three months ended March 31, 2014 , a de crease of $1.9 million or 2.4% . The de crease was primarily in our MES segment due to de crease s in cost of disposable sales of $1.9 mill ion and other rental costs of $1 .2 million and a decrease in medical equipment depreciation of $1.0 million . The decrease s were partially offset by the increase in our MES segment due to increase s in 360 solutions cost of $ 1.2 million and an increase in our CES 360 solutions cost of $1.3 million corresponding with the 360 solutions revenue growth.
Gross Margin
Total gross margin for the three months ended March 31, 2015 was $36.7 million, or 32.3% of total revenues, compared to $34.7 million, or 30.6% of total revenues , for the three months ended March 31, 2014 , an in crease of $2.0 million or 5.8% . The in crease in gross margin as a percent of revenue for the quarter was primarily impacted by a business mix shift from lower margin disposable sales to higher margin 360 solutions in the M ES segment, coupled with positive operating leverage from volume growth and some shift to higher margin modalities in the SS portions of the business . In addition, the gross margin increase in the CES segment was primarily impacted by lower vendor expense. CES gross margin percentage will fluctuate based on the variability of third-party vendor expenses in our 360 solutions and supplemental service programs.
Medical Equipment Solutions
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
||||
|
|
March 31, |
|
|
|
|
|
|
||||
|
|
2015 |
|
2014 |
|
Change |
|
% Change |
|
|||
Total revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
|
% |
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Medical equipment depreciation |
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin |
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
Gross margin % |
|
|
|
% |
|
|
% |
|
|
|
|
|
Total revenue in the MES segment decreased $2.6 million, or 3.4% , to $74.1 m illion in the first quarter of 2015 as compared to the same period of 2014 . The decrease was primarily due to the decline in NPWT device rental and disposable sales due to the interruption of Smith & Nephew commercial distribution of the RENASYS product line of approximately $4.0 million and the transition of certain customers related to the loss of the national GPO contract of $2.1 million . The decrease was partially offset by growth in our 360 solutions from both new programs and expans ion of existing programs of $2.6 million . Many of our 360 Solution customers utilize more than one of our equipment management program offerings in areas such as infusion, patient handling and negative pressure wound therapy. As of March 31, 2015 , we had 215 s uch active programs, up from 209 as of December 31, 2014 .
28
Total c ost of revenue in the segment de creased $2.1 million, or 6.4% , to $31.3 million in the first quarter of 2015 as compared to the same period of 2014 . This decrease wa s due to lower cost of disposable sales of $1.9 million a nd decrease in rental cost of $1 .2 million largely due to lower payroll, vehicle and freight expenses . The decrease was partially offset by an increase in costs to support gro wth in our 360 solutions of $ 1 .2 million largely due to increase s in employee related expense of $ 0.8 million and repair parts of $0.5 million .
Medical equipment depreciation decreased $1.1 million, or 6.4% , to $16.7 million in the first quarter of 2015 as compared to the same period of 2014 . The decrease in medical equipment depreciation was primarily due to reduced depreciation resulting from disposals of certain medical equipment.
Gross margin p ercentage for the MES segment in creased from 33.2% in the first quarter of 2014 to 35.3% in the same period of 2015 . Gross margin rate was impacted by the lower depreciation, growth in our 360 solutions and a business mix shift from lower margin disposable sales to higher margin 360 solutions .
Future revenue will continue to be negatively impacted by the loss of revenues resulting from the pending FDA 510(k) clearances on RENASYS NPWT product line and the loss of the agreement related to a national GPO.
Clinical Engineering Solutions
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
||||
|
|
March 31, |
|
|
|
|
|
|
||||
|
|
2015 |
|
2014 |
|
Change |
|
% Change |
|
|||
Total revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
|
% |
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin |
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
Gross margin % |
|
|
|
% |
|
|
% |
|
|
|
|
|
Total revenue in the CES segment increased $1.7 million, or 7.6% , to $24.4 million in the first quarter of 2015 as compared to the same period of 2014 . The increase was primarily due to growth in our managed 360 solutions . As of March 31, 2015 , we had 360 solutions implemented in 149 programs in our CES segment, up from 144 programs as of December 31, 2014 .
Total cost of revenue in the segment increased $1.3 million, or 7.3% , to $19.2 million in the first quarter of 2015 as compared to the same period of 2014 . The increase is primarily attributable to increase s in vendor expenses and employee related costs to support the revenue growth and mix shifts in type of service provided to customers.
Gross margin p ercentage for the CES segment in creased from 21.0% in the first quarter of 2014 to 21.2% in the same period of 2015 . Gross margin percentage will fluctuate based on the variability of third-party vendor expenses in our 360 solutions and supplemental service programs.
Surgical Services
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
||||
|
|
March 31, |
|
|
|
|
|
|
||||
|
|
2015 |
|
2014 |
|
Change |
|
% Change |
|
|||
Total revenue |
|
$ |
|
|
$ |
|
|
$ |
|
|
|
% |
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Medical equipment depreciation |
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin |
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
Gross margin % |
|
|
|
% |
|
|
% |
|
|
|
|
|
Total revenue in the SS segment increased $1.1 million, or 7.6% , to $15.0 million in the first quarter of 2015 as compared to the same period of 2014 . The increase was driven by organic growth in our surgical services business.
29
Total cost of revenue in the segment was $8.2 million both in the first quarter of 2015 and 2014.
Medical equipment depreciation increased $0.1 million, or 10.9% , to $1.5 million in the first quarter of 2015 as compared to the same period of 2014 . The increase was primarily due to additional medical equipment purchased .
Gross margin percentage for the SS segment increased from 31.7% in the first quarter of 2014 to 35.7% in the same period of 2015 . The increase in gross margin percentage was primarily driven by both positive operating leverage from volume growth and some shift to higher margin modalities.
Selling, General and Administrative , Restructuring, Acquisition and Integration Expenses and Interest Expense
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
||||
|
|
March 31, |
|
|
|
|
|
|
||||
|
|
2015 |
|
2014 |
|
Change |
|
% Change |
|
|||
Selling, general and administrative |
|
$ |
|
|
$ |
|
|
$ |
|
|
|
% |
Restructuring, acquisition and integration expenses |
|
|
— |
|
|
|
|
|
|
|
* |
|
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
*Not meaningful
Selling, General and Administrative
Selling, gener al and administrative expense in creased $0.9 million, or 2.9% , to $30.2 million for the first quarter of 2015 as compared to the same period of 2014 . The increase was primarily due to increases in consulting and legal fees.
Selling, general and administrative expense as a percentage of total revenue was 26.6% and 25.8% for the quarter ended March 31, 2015 and 2014 , respectively.
Restructuring, Acquisition and Integration Expenses
Restructuring, acquisition and integration expenses for the first quarter of 2014 was primarily due to additional changes to realign the management team.
Interest Expense
Interest expense decreased $0.1 million to $13.3 million for the first quarter of 2015 as compared to the same period of 2014 .
Income Taxes
Income taxes were an expense of $0.2 and $0.2 million for the three months ended March 31, 2015 and 2014 , respectively. The tax expense for the three months ended March 31, 2015 and 2014 primarily related to state minimum fees . The Company will continue to incur deferred tax expense in the future as tax amortization occurs. The expected tax benefit from operating loss during the three months ended March 31, 2015 was offset by the recording of additional valuation allowance. In future reporting periods, we will continue to assess the likelihood that deferred tax assets will be realizable.
Consolidated Net Loss
Consolidated net loss de creased $2.6 million to $7.0 million in the first quarter of 2015 as compared to the same period of 2014 . Net los s was impacted by higher margin rates as well as the decreases in medical equipment depreciation and restructuring expense.
30
EBITDA
Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) was $30.8 and $29.7 million for the three months ended March 31, 2015 and 2014 , respectively. EBITDA for the three months ended March 31, 2015 , was impacted by growth in our SS segment combined with a decrease in restructuring expense.
In addition to using EBITDA internally as a measure of operational performance, we disclose it externally to assist analysts, investors and lenders in their comparisons of operational performance, valuation and debt capacity across companies with differing capital, tax and legal structures. EBITDA, however, is not a measure of financial performance under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to, or more meaningful than, net income as a measure of operating performance or to cash flows from operating, investing or financing activities or as a measure of liquidity. Since EBITDA is not a measure determined in accordance with GAAP and is thus susceptible to varying interpretations and calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. EBITDA does not represent an amount of funds that is available for management’s discretionary use. A reconciliation of net loss attributable to UHS to EBITDA is included below:
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
||||
|
|
March 31, |
|
||||
(in thousands) |
|
2015 |
|
2014 |
|
||
Net loss attributable to Universal Hospital Services, Inc. |
|
$ |
|
|
$ |
|
|
Interest expense |
|
|
|
|
|
|
|
Provision for income taxes |
|
|
|
|
|
|
|
Depreciation and amortization of intangibles |
|
|
|
|
|
|
|
EBITDA |
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
Other Financial Data: |
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
$ |
|
|
$ |
|
|
Net cash used in investing activities |
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Operating Data (as of end of period): |
|
|
|
|
|
|
|
Medical equipment (approximate number of owned outsourcing units) |
|
|
|
|
|
|
|
District service centers |
|
|
|
|
|
|
|
SS stand-alone service centers |
|
|
|
|
|
|
|
Centers of Excellence |
|
|
|
|
|
|
|
SEASONALITY
Quarterly operating results are typically affected by seasonal factors. Historically, our first and fourth quarters are the strongest, reflecting increased customer utilization during the fall and winter months.
LIQUIDITY AND CAPITAL RESOURCES
Original Notes and Add-on Notes — 7.625%. On August 7, 2012, we issued $425.0 million in aggregate principal amount of 7.625% Second Lien Senior Secured Notes due 2020 (the “Original Notes”) under an indenture dated as of August 7, 2012 (the “2012 Indenture”). On February 12, 2013, we issued $220.0 million in aggregate principal amount of 7.625% Second Lien Senior Secured Notes due 2020 (the “Add-on Notes”, and along with the Original Notes, the “2012 Notes”) as “additional notes” pursuant to the 2012 Indenture . The 2012 Notes mature on August 15, 2020.
The 2012 Indenture provides that the 2012 Notes are our second lien senior secured obligations and are fully and unconditionally guaranteed on a second lien senior secured basis by our existing and certain of our future 100%-owned domestic subsidiaries.
Our principal sources of liquidity are expected to be cash flows from operating activities and borrowings under our senior secured credit facility, which provides for loans in an amount of up to $235.0 million, subject to our borrowing
31
base. See Note 8, Long-Term Debt for details related to our senior secured credit facility. It is anticipated that our principal uses of liquidity will be to fund capital expenditures related to purchases of medical equipment, provide working capital, meet debt service requirements and finance our strategic plans.
We require substantial cash to operate our health care technology solutions and service our debt. Our health care technology solutions require us to invest a significant amount of cash in medical equipment purchases. To the extent that such expenditures cannot be funded from our operating cash flow, borrowing under our senior secured credit facility or other financing sources, we may not be able to conduct our business or grow as currently planned.
If we are unable to generate sufficient cash flow from operations in order to service our debt, we will be forced to take actions such as reducing or delaying capital expenditures, selling assets, restructuring or refinancing our debt, or seeking additional equity capital. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control. If we are unable to repay our debt at maturity, we may have to obtain alternative financing, which may not be available to us.
Future cash flows from operations will continue to be negatively impacted by the loss of revenues resulting from the pending FDA 510(k) clearances on RENASYS NPWT product line and the loss of the agreement related to a national GPO.
Net cash provided by operating activities was $11.8 and $8.1 million for the three months ended March 31, 2015 and 2014 , respectively. The increase in net cash provided by operating activities was primarily due to the decreases in net loss during 2015 compared to the same period of 2014.
Net cash used in investing activities was $18.8 and $22.2 million for the three months ended March 31, 2015 and 2014 , respectively. The decrease in net cash used in investing activities was primarily due to higher proceeds from sale of medical equipment and lower medical equipment purchases during 2015 compared to the same period of 2014 .
Net cash provided by financing activities was $7.0 and $14.0 million for the three months ended March 31, 2015 and 2014 , respectively. The decrease in net cash provided by financing activities was primarily due to lower net borrowings in 2015 compared to the same period of 2014 .
Based on the level of operating performance expected in 2015 , we believe our cash from operations and additional borrowings under our senior secured credit facility, will meet our liquidity needs for the foreseeable future, exclusive of any borrowings that we may make to finance potential acquisitions. However, if during that period or thereafter we are not successful in generating sufficient cash flows from operations or in raising additional capital when required in sufficient amounts and on terms acceptable to us, our business could be adversely affected . As of March 31, 2015 , we had $123.6 million of availability under the senior secured credit facility based on a borrowing base of $177.2 million less borrowings of $50.0 million and after giving effect to $3.6 million used for letters of credit. As of March 31, 2014 , we had $ 137 .4 million of availability under the senior secured credit facility based on a borrowing base of $ 196.7 million less borrowings of $ 55.1 million and after giving effect to $4.2 million used for letters of credit.
Our levels of borrowing are further restricted by the financial covenants set forth in our senior secured credit facility agreement and the 2012 Indenture governing our 2012 Notes, as described in Note 8, Long-Term Debt.
The Company was in compliance with all financial covenants for all periods presented.
RECENT ACCOUNTING PRONOUNCEMENT
See Item 1 of Part I, Note 2, Recent Accounting Pronouncements.
SAFE HARBOR STATEMENT
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: We believe statements in this Quarterly Report on Form 10-Q looking forward in time involve risks and uncertainties. The following factors, among
32
others, could adversely affect our business, operations and financial condition, causing our actual results to differ materially from those expressed in any forward-looking statements:
|
· |
|
our competitors’ activities; |
|
· |
|
our customers’ patient census or service needs; |
|
· |
|
global economic conditions’ effect on our customers; |
|
· |
|
our ability to maintain existing contracts or contract terms and enter new contracts with customers; |
|
· |
|
uncertainties as to the effect of non-renewal of existing contracts; |
|
· |
|
consolidation in the health care industry and its effect on prices; |
|
· |
|
our relationships with key suppliers; |
|
· |
|
our ability to change the manner in which health care providers procure medical equipment; |
|
· |
|
the absence of long-term commitments and cancellations by or disputes with customers; |
|
· |
|
our dependence on key personnel; |
|
· |
|
our ability to identify and manage acquisitions; |
|
· |
|
increases in expenses related to our pension plan; |
|
· |
|
our cash flow fluctuation; |
|
· |
|
the increased credit risks associated with doing business with home care providers and nursing homes; |
|
· |
|
the risk of claims associated with medical equipment we outsource and service; |
|
· |
|
increases costs we cannot pass through; |
|
· |
|
the failure of any management information system; |
|
· |
|
the inherent limitations on internal controls of our financial reporting; |
|
· |
|
the uncertainty surrounding health care reform initiatives; |
|
· |
|
the federal Privacy law risks; |
|
· |
|
the federal Anti-Kickback law risks; |
|
· |
|
changes to third-party payor reimbursement for health care items and services; |
|
· |
|
potential other new healthcare laws or regulations; |
|
· |
|
our customers operate in a highly regulated environment; |
|
· |
|
our fleet’s risk of recalls or obsolescence; |
|
· |
|
our substantial debt service obligations; |
|
· |
|
our need for substantial cash to operate and expand our business as planned; and |
|
· |
|
our history of net losses and s ubstantial interest expense. |
For further information on risk applicable to us, please see the disclosure regarding the risk factors as set forth in Item 1A of Part II of this Quarterly Report on Form 10-Q.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
We are exposed to market risk arising from adverse changes in interest rates, fuel costs and pension valuation. We do not enter into derivatives or other financial instruments for speculative purposes.
Interest Rates
We use both fixed and variable rate debt as sources of financing. At March 31, 2015 , we had approximately $724.5 million of total debt outstanding of which $50.0 million was bearing interest at variable rates. Based on variable debt levels at March 31, 2015 , a 1.0 percentage point change in interest rates on variable rate debt would have resulted in annual interest expense fluctuating by approximately $0.5 million.
Fuel Costs
We are also exposed to market risks related to changes in the price of gasoline used to fuel our fleet of delivery and sales vehicles. A hypothetical 10% increase in the first three months of 2015 average price of unleaded gasoline, assuming gasoline usage levels for the three months ended March 31, 2015 , would lead to an annual increase in fuel costs of approximately $0.4 million.
33
Pension
Our pension plan assets, which were approximately $20.6 million at December 31, 2014 , are subject to volatility that can be caused by fluctuations in general economic conditions. Continued market volatility and disruption could cause further declines in asset values, and if this occurs, we may need to make additional pension plan contributions and our pension expense in future years may increase. A hypothetical 10% decrease in the fair value of plan assets at December 31, 2014 would lead to a decrease in the funded status of the plan of approximately $2.1 million.
Other Market Risk
As of March 31, 2015 , we have no other material exposure to market risk.
Item 4. Controls and Procedures
|
(a) |
|
Evaluation of disclosure controls and procedures |
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934 as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2015 .
|
(b) |
|
Changes in internal control over financial reporting |
There were no changes that occurred during the most recent fiscal quarter that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.
The Company, in the ordinary course of business, could be subject to liability claims related to employees and the equipment that it rents and services. Asserted claims are subject to many uncertainties and the outcome of individual matters is not predictable. While the ultimate resolution of these actions may have an impact on the Company’s financial results for a particular reporting period, management believes that any such resolution would not have a material adverse effect on the financial position, results of operations or cash flows of the Company and the chance of a negative outcome on outstanding litigation is considered remote. See the additional information in Item 1 of Part I, Note 9, Commitments and Contingencies.
Our business is subject to various risks and uncertainties. Any of the risks discussed elsewhere in this Quarterly Report on Form 10-Q or our other filings with the Securities and Exchange Commission, including the risk factors set forth in our 2014 Annual Report on Form 10-K, could materially adversely affect our business, financial condition or results of operations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults upon Senior Securities
None.
34
Item 4. Mine Safety Disclosures
Not applicable.
None.
|
|
|
Number |
|
Description |
|
|
|
|
|
Employment Agreement dated April 8, 2015 between Thomas Leonard and Universal Hospital Services, Inc. |
|
|
|
|
|
Restricted Stock Unit Award Agreement dated April 13, 2015 between UHS Holdco, Inc. and Thomas Leonard. |
|
|
|
|
|
Form of Option Agreement Evidencing a Grant of an Option Under the 2007 Stock Option Plan dated May 8, 2015 between UHS Holdco, Inc. and Thomas Leonard. |
|
|
|
|
|
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
Financial Statements from the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2015 , formatted in Extensible Business Reporting Language: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Loss, (iv) the Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements. |
35
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 13, 2015
|
|
|
|
Universal Hospital Services, Inc. |
|
|
|
|
|
By |
/s/ Thomas J. Leonard |
|
Thomas J. Leonard |
|
|
Chief Executive Officer |
|
|
(Principal Executive Officer and Duly Authorized Officer) |
|
|
|
|
|
By |
/s/ James B. Pekarek |
|
James B. Pekarek |
|
|
Executive Vice President and Chief Financial Officer |
|
|
(Principal Financial Officer) |
36
EXECUTION VERSION
THIS EMPLOYMENT AGREEMENT (this “ Agreement ”) is entered into as of April 8 , 20 1 5 , by and between Thomas Leonard (“ Executive ”) and Universal Hospital Services, Inc., a Delaware corporation (the “ Company ”).
WHEREAS , the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms set forth in this Agreement ; and
WHEREAS , the Executive shall commence employment on April 13, 2015 (the “ Effective Date ”) .
NOW , THEREFORE , for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
|
2. Employment Duties . Executive shall have the title of Chief Executive Officer of the Company and shall have such duties, authorities and responsibilities as are consistent with such position and as the Board of Directors of the Company (the “ Board ”) may designate from time to time. Executive shall report directly to the Board. Executive shall devote his full working time and attention and Executive’s best efforts to Executive’s employment and service with the Company and shall perform Executive’s services in a capacity and in a manner consistent with Executive’s position for the Company; provided , that this Section 2 shall not be interpreted as prohibiting Executive from (i) managing Executive’s personal investments (so long as such investment activities are of a passive nature), (ii) engaging in charitable or civic activities, (iii) participating on boards of directors or similar bodies of non-profit org anizations, or ( i v) subject to approval by the Board in its sole discretion, participating on boards of directors or similar bodies of for-profit organizations, in each case of (i) – ( i v), so long as such activities do not, individually or in the aggregate, (a) materially interfere with the performance of Executive’s duties and responsibilities hereunder, (b) create a fiduciary conflict, or (c) result in a violation of Section 16 of this Agreement. If requested, Executive shall also serve as an executive officer and/or board member of the board of directors (or similar gov erning body) of any entity that is a Subsidiary of the Company, without any additional compensation. |
|
5. Benefits . During the Term, Executive shall be entitled to participate in any benefit plans, including medical, disability and life insurance (but excluding any severance or bonus plans unless specifically referenced in this Agreement) offered by the Company as in effect from time to time (collectively, “ Benefit Plans ”), on the same basis as those generally made available to other senior executives of the Company, to the extent consistent with applicable law and the terms of the applicable Benefit Plan. The Company does not promise the adoption or continuance of any particular Benefit Plan and reserves the right to amend or cancel any Benefit Plan at any time in its sole discretion (subject to the terms of such Benefit Plan and applicable law). |
|
6. Vacation . Executive shall be entitled to five ( 5 ) weeks of annual paid vacation days, which shall accrue and be useable by Executive in accordance with Company policy, as may be in effect from time to time. |
|
(a) Business Expenses. The Executive shall be entitled to reimbursement for all reasonable and necessary out-of-pocket business, entertainment and travel expenses incurred by the Executive in connection with the performance of the Executive's duties hereunder in accordance with the Company's expense reimbursement policies and procedures. |
|
(b) Long Distance Travel and Housing. The Company shall reimburse Executive for expenses related to travel from his home in Encinitas , California to Minneapolis, MN and provide Executive with a rental apartment in Minneapolis, MN. To the extent that the reimbursement of any am ounts pursuant to this Section 7 (b) is taxable to the Executive, the Executive will be grossed up for income tax at Executive’s marginal income tax rate for such amount. |
|
8. Relocation . At Executive’s election, Executive may relocate his primary residence to the Minneapolis metropolitan area (although no such relocation is required) and the Company shall , subject to the Company’s Executive Relocation Policy which will be provided to Executive , reimburse Executive for all reasonable relocation expenses incurred by Executive in connection with such relocation (including, moving expenses and closing costs relating to the purchase of a new home) , subject to presentation by Executive of documentation reasonably
2
|
satisfactory to the Company that the applicable expense has been incurred. Executive shall promptly repay the gross amount of all payments made by the Company pursuant to this Section 8 if, prior to the one year anniversary of Executive’s relocation , Executive’s employment is terminate d by the Company for Cause or Executive resigns without Good Reason. To the extent that the reimbursement of any amounts pursuant to this Section 8 is taxable to the Executive, the Executive will be grossed up for income tax at Executive’s marginal income tax rate for such amount. |
|
10. Termination of Employment . The Term and Executive’s employment hereunder may be terminated as follows: |
|
(a) Automatically in the event of the death of Executive; |
|
(b) At the option of the Company, by written notice to Executive or Executive’s personal representative in the event of the Disability of Executive. As used herein, the term “ Disability ” shall mean the Executive is disabled within the meaning of the Company’s long-term disability policy then in effect ; |
|
(c) At the option of the Company for Cause, on prior written notice to Executive; |
|
(d) At the option of the Company at any time without Cause (provided that the assignment of this Agreement to, and assumption of this Agreement by, the purchaser of all or substantially all of the assets of the Company shall not be treated as a termination without Cause under this Section 1 0 (d) ), by delivering written notice of its determination to terminate to Executive; |
|
(e) At the option of Executive for Good Reason; |
|
(f) At the option of Executive without Good Reason, upon ninety ( 9 0) days prior written notice to the Company (which the Company may, in its sole discretion, make effective as a resignation earlier than the termination date provided in such notice ; provided that the Company shall continue to pay Executive his Base Salary for such ninety (90) day period ), or |
|
(i) (A) within ten ( 10 ) days following such termination, (i) payment of Executive’s accrued and unpaid Base Salary , (ii) payment for any accrued but unused vacation days, (iii) payment of any earned but unpaid Annual Bonus with respect to the year prior to the
3
|
year of termination a nd (i v ) reimbursement of expenses under Section 7 of this Agreement, in each case of (i) through (i v ), accrued through the date of termination and (B) all other accrued amounts or accrued benefits due to Executive in accordance with the Company’s benefit plans, programs or policies (other than severance); |
|
(ii) an amount equal to the sum of (A) twelve (12) months of Executive’s Base Salary as in effect immediately prior to Executive’s date of termination and (B) Executive’s Target Bonus Opportunity for the year of termination , which sum shall be payable during the twelve (12) month period commencing on the date of termination (the “ Severance Period ”) in substantially equal installments in accordance with the Company’s regular payroll practices as in effect from time to time , provided , that the first payment pursuant to this Section 1 1 (a)(ii) shall be made on the next regularly scheduled payroll date following the sixtieth (60th) day after Executive’s termination and shall include payment of any amounts that would otherwise be due prior thereto ; and |
|
(iii) an amount equal to the pro-rata portion of Executive’s Annual Bonus for the year of termination, based on the number of days the Executive is employed during such year , if such bonus would otherwise have been earned and payable had Executive’s employment not been terminated, payable in a lump-sum on such date as the Company generally pays Annual Bonuses to other senior executives of the Company (“ Pro-rata Bonus ”) ; and |
|
(iv) subject to Executive’s timely election of continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“ COBRA ”), the Company shall pay to Executive each month an amount equal to the monthly amount of the COBRA continuation coverage premium under the Company’s group medical plans as in effect from time to time less the amount of Executive’s portion of the premium as if Executive was an active employee under the same terms as provided to senior executive officers of the Company until the earliest of (i) twelve (12 ) months after the date of Execut ive’s termination of employment; (ii) the date Executive is no longer eligible for benefits under COBRA; or (iii) the date Executive obtains other employment that offers medical benefits, provided , that the first payment pursuant to this Section 1 1 (a)(iv) shall be made on the next regularly scheduled payroll date following the sixtieth (60th) day after Executive’s termination and shall include payment of any amounts that would otherwise be due prior thereto. |
|
(b) Termination by the Company With Cause or by Executive Without Good Reason . If the Company terminates Executive’s emplo yment for Cause during the Term or Executive terminates his employment with out Good Reason during the Term , Executive shall be entitled to receive the payments and benefits described under Section 1 1 (a)(i) of this Agreement. |
|
(c) Termination due to Executive’s Death or Disability . If Executive’s employment terminates during the Term due to death or Disability, Executive or Executive’s legal representatives, as applicable, shall be entitle d to the Pro-rata Bonus and the payments and benefits described under Section 1 1 (a)(i) of this Agreement. |
|
(d) Conditions to Payment . All payments and benefits due to Executive under this Section 1 1 which are not otherwise required by applicable law shall be payable only if Executive executes and delivers to the Company a general release of claims in a form reasonably satisfactory to the Company and such release is no longer subject to revocation (to the extent
4
|
applicable), in each case, within sixty (60) days following termination of employment. Failure to timely execute and return such release or revocation thereof shall be a waiver by Executive of Executive’s right to severance (which, for the avoidance of doubt, shall not include any amounts described in Section 1 1 (a)(i) of this Agreement). In addition, severance shall be conditioned on Executive’s continued compliance with Section 16 of this Agreement as provided in Section 1 7 below. |
|
(e) No Other Severance . Executive hereby acknowledges and agrees that, other than the severance payments described in this Section 1 1 , upon the effective date of the termination of Executive’s employment, Executive shall not be entitled to any other severance payments or benefits of any kind under any Company benefit plan, severance policy generally available to the Company’s employees or otherwise and a ll other rights of Executive to compensation under this Agreement shall end as of such date. |
|
12. Definitions . For purposes of this Agreement, |
|
(a) “ Affiliate ” shall mean any entity that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, the Company. |
|
(c) “ Good Reason ” shall mean, without Executive’s consent, (i) any material diminution in Executive’s responsibilities, authorities or duties ; provided that in the event of Executive’s Disability, the Company’s appointment of an interim Chief Executive Officer shall not constitute a diminution of Executive’s responsibilities, authorities or duties , (ii) any reduction in Exec utive’s (x) Base Salary or (y) T arget Bonus O pportunity (except in the event of an across the boa rd reduction in Base Salary or T arget Bonus O pportunity applicable to substantially all senior executives of the Company), or (iii) a relocation of Executive’s place of employment by more than fifty (50) miles; provided , that no event described in clause (i), (ii), or (iii) shall constitute Good Reason unless (A) Executive has given the Company written notice of the termination, setting forth the conduct of the Company that is alleged to constitute Good Reason, within thirty (30) days following he occurrence of such event, and (B) Executive has provided the Company at least sixty (60) days following the date on which such notice is provided to cure such conduct and the Company has failed to do so. Failing such cure, a termination of employment by Executive for Good Reason shall be effective on the day following the expiration of such cure period. |
5
|
14. Resignation as Officer or Director . Upon the effective date of any Executive’s termination, Executive shall be deemed to have resigned, to the extent applicable, as an officer of the Company, as a member of the board of directors or similar governing body of the Company or any of its Affiliates, and as a fiduciary of any Company benefit plan. On or immediately following the effective date of any such termination of Executive’s employment, Executive shall confirm the foregoing by submitting to the Company in writing a confirmation of Executive’s resignation(s). |
|
15. Confidentiality; Non-Solicitation; Non-Competition . |
|
(a) Confidential and Proprietary Information . The Executive agrees that during and at all times after the Term, the Executive will keep secret all confidential matters and materials of the Company (including its subsidiaries and affiliates), including, without limitation, know-how, trade secrets, real estate plans and practices, individual office results, customer lists, pricing policies, operational methods, any information relating to the Company (including any of its subsidiaries and affiliates) products, processes, customers and services and other business and financial affairs of the Company (collectively, the “ Confidential Information ” ), to which the Executive had or may have access and will not disclose such Confidential Information to any person, other than (i) the Company, its respective authorized employees and such other persons to whom the Executive has been instructed to make disclosure by the Board, (ii) as appropriate (as determined by the Executive in good faith) to perform his duties hereunder, or (iii) in compliance with legal process or regulatory requirements. “Confidential Information” will not include any information which is in the public domain during or after the Term, provided such information is not in the public domain as a consequence of disclosure by the Executive in violation of this Employment Agreement. The Executive acknowledges that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports, patent applications, copyrightable work and mask work (whether or not including any confidential information) and all registrations or applications related thereto, all other proprietary information and all similar or related information (whether or not patentable) which relate to the Company’s or any of its s ubsidiaries’ actual or anticipated business, research and development or existing or future products or services and which are
6
|
|
(b) Non-Solicitation . Executive hereby acknowledges and agrees that during Executive’s employment with the Company and for a period of one (1) year commencing with the date of Executive’s termination of employment with the Company (the “ Restricted Period ”), Executive shall not, without the written consent of the Board, directly or indirectly, on Executive’s behalf or the behalf of a third party, hire, solicit, persuade or induce to leave, or attempt to do any of the foregoing, any person who is employed by, or performing services as an independent contractor for, the Company or any of its Affiliates as of the date of Executive’s termination (or who was an employee or independent contractor of the Company or any of its Affiliates at any time during the twelve (12) months preceding Executive’s date of termination). |
|
(d) Tolling . In the event of any violation of the provisions of this Section 1 5 , Executive acknowledges and agrees that the post-termination restrictions contained in this Section 1 5 shall be extended by a period of time equal to the period of such violation, it being the intention of the parties hereto that the running of the applicable post-termination restriction period shall be tolled during any period of such violation. |
|
16. Cooperation . From and after Executive’s termination of employment, Executive shall provide Executive’s reasonable cooperation in connection with any action or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive’s employment hereunder, provided , that the Company shall reimburse Executive for Executive’s reasonable costs and expenses (including legal counsel selected by Executive and reasonably acceptable to the Company) and such cooperation shall not unreasonably burden Executive or unreasonably interfere with any subsequent employment that Executive may undertake. |
a federal or state court in Minnesota to enforce the provisions of Sections 1 3 , 1 5 and/or 1 6 without the necessity of posting a bond or proving actual damages, without liability should such relief be denied, modified or vacated . Each party shall be responsible for his or its own attorney’s fees in respect of a ny such action or proceeding. Additionally, in the event of a breach or threatened breach by Executive of Section 15 , in addition to all other available legal and equitable rights and remedies, the Company shall have the right to cease making payments, if any, being made pursuant to Section 11 (a)(ii) hereunder. Executive also recognizes that the territorial, time and scope limitations set forth in Section 1 5 are reasonable and are properly required for the protection of the Company and its Affiliates and in the event that any such territorial, time or scope limitation is deemed to be unreasonable by a court of competent jurisdiction, the Company and Executive agree, and Executive submits, to the reduction of any or all of said territorial, time or scope limitations to such an area, period or scope as said court shall deem reasonable under the circumstances. |
|
(a) All notices hereunder, to be effective, shall be in writing and shall be deemed effective when delivered by hand or mailed by (i) certified mail, postage and fees prepaid, or (ii) nationally recognized overnight express mail service, as follows: |
If to the Company:
Universal Hospital Services, Inc.
6625 West 78th Street, Suite 300
Minneapolis, MN 55439
Attn: Lee Pulju
With a copy to:
Irving Place Capital
745 Fifth Avenue
New York, NY 10151
Attn: Bob Juneja
If to Executive:
At his home address as then shown in the Company’s personnel records,
or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt.
|
(b) This Agreement is personal to the Executive and shall not be assigned by the Executive. Any purported assignment by the Executive shall be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and its successors and assigns. |
8
|
(c) This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes all other agreements, term sheets, offer letters, and drafts thereof, oral or written, between the parties hereto with respect to the subject matter hereof. No promises, statements, understandings, representations or warranties of any kind, whether oral or in writing, express or implied, have been made to Executive by any person or entity to induce him to enter into this Agreement other than the express terms set forth herein, and Executive is not relying upon any promises, statements, understandings, representations, or warranties other than those expressly set forth in this Agreement. |
|
(d) No change or modification of this Agreement shall be valid unless the same shall be in writing and signed by all of the parties hereto. No waiver of any provisions of this Agreement shall be valid unless in writing and signed by the party charged with waiver. No waiver of any of the provisions of this Agreement shall be deemed, or shall constitute, a waiver of any other provision, whether or not similar, nor shall any waiver constitute a continuing waiver, unless so provided in the waiver. |
|
(e) If any provisions of this Agreement (or portions thereof) shall, for any reason, be held invalid or unenforceable, such provisions (or portions thereof) shall be ineffective only to the extent of such invalidity or unenforceability, and the remaining provisions of this Agreement (or portions thereof) shall nevertheless be valid, enforceable and of full force and effect. If any court of competent jurisdiction finds that any restriction contained in this Agreement is invalid or unenforceable, then the parties hereto agree that such invalid or unenforceable restriction shall be deemed modified so that it shall be valid and enforceable to the greatest extent permissible under law, and if such restriction cannot be modified so as to make it enforceable or valid, such finding shall not affect the enforceability or validity of any of the other restrictions contained herein. |
|
(f) This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof. |
|
(h) Notwithstanding anything to the contrary in this Agreement: |
|
(i) The parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the Code and the regulations and authoritative
9
|
guidance promulgated thereunder to the extent applicable (collectively “ Section 409A ”), and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. In no event whatsoever will the Company, any of its affiliates, or any of their respective directors, officers, agents, attorneys, employees, executives, shareholders, investors, members, managers, trustees, fiduciaries, representatives, principals, accountants, insurers, successors or assigns be liable for any additional tax, interest or penalties that may be imposed on Executive under Section 409A or any damages for failing to comply with Section 409A. |
|
(ii) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits considered “nonqualified deferred compensation” under Section 409A upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A, and for purposes of any such provision of this Agreement, references to a “resignation,” “termination,” “terminate,” “termination of employment” or like terms shall mean separation from service. If any payment, compensation or other benefit provided to the Executive in connection with the termination of his employment is determined, in whole or in part, to constitute “nonqualified deferred compensation” within the meaning of Section 409A and the Executive is a specified employee as defined in Section 409A(2)(B)(i) of the Code, no part of such payments shall be paid before the day that is six (6) months plus one (1) day after the date of termination or, if earlier, ten business days following the Executive’s death (the “ New Payment Date ”). The aggregate of any payments that otherwise would have been paid to the Executive during the period between the date of termination and the New Payment Date shall be paid to the Executive in a lump sum on such New Payment Date. Thereafter, any payments that remain outstanding as of the day immediately following the New Payment Date shall be paid without delay over the time period originally scheduled, in accordance with the terms of this Agreement. |
|
(iii) All reimbursements for costs and expenses under this Agreement shall be paid in no event later than the end of the calendar year following the calendar year in which the Executive incurs such expense. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (ii) the amount of expenses eligible for reimbursements or in-kind, benefits provided during any taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other taxable year. |
|
(iv) I f under this Agreement, an amount is paid in two or more installments, for purposes of Section 409A, each installment shall be treated as a separate payment. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g., “payment shall be made within thirty (30) days following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company. |
jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance of any such action or proceeding in such venue. |
|
(j) Other than the Company’s right to seek injunctive relief or specific performance as provided in this Agreement, any dispute, controversy, or claim between the Executive, on the one hand, and the Company, on the other hand, arising out of, under, pursuant to, or in any way relating to this Agreement and Executive’s employment shall be submitted to and resolved by confidential and binding arbitration (“ Arbitration ”), administered by the American Arbitration Association (“ AAA ”) and conducted pursuant to the rules then in effect of the AAA governing commercial disputes. The Arbitration hearing shall take place in Minneapolis , Minnesota . Such Arbitration shall be before three neutral arbitrators (the “ Panel ”) licensed to practice law and familiar with commercial disputes. Any award rendered in any Arbitration shall be final and conclusive upon the parties to the Arbitration and not subject to judicial review, and the judgment thereon may be entered in the highest court of the forum (state or federal) having jurisdiction over the issues addressed in the Arbitration, but entry of such judgment will not be required to make such award effective. The Panel may enter a default decision against any party who fails to participate in the Arbitration. The administration fees and expenses of the Arbitration shall be borne equally by the parties to the Arbitration; provided that each party shall pay for and bear the cost of his/her/its own experts, evidence, and attorney’s fees, except that, in the discretion of the Panel, any award may include the costs of a party’s counsel and/or its share of the expense of Arbitration if the Panel expressly determines that an award of such costs is appropriate to the party whose position substantially prevails in such Arbitration. Notwithstanding any other provision of this Agreement, no party shall be entitled to an award of special, punitive, or consequential damages. To submit a matter to Arbitration, the party seeking redress shall notify in writing, in accordance with Section 1 8 (a) of this Agreement, the party against whom such redress is sought, describe the nature of such claim, the provision of this Agreement that has been allegedly violated and the material facts surrounding such claim. The Panel shall render a single written, reasoned decision. The decision of the Panel shall be binding upon the parties to the Arbitration, and after the completion of such Arbitration, the parties to the Arbitration may only institute litigation regarding the Agreement for the sole purpose of enforcing the determination of the Arbitration hearing or, with respect to the Company, to seek injunctive or equitable relief pursuant to Section 1 7 of this Agreement. The Panel shall have exclusive authority to resolve any dispute relating to the interpretation, applicability, enforceability or formation of this agreement to arbitrate, including any claim that all or part of this Agreement is void or voidable and any claim that an issue is not subject to arbitration. All proceedings conducted pursuant to this agreement to arbitrate, including any order, decision or award of the arbitrator, shall be kept confidential by all parties except to the extent such disclosure is required by law, or in a proceeding to enforce any rights under this Agreement. |
EXECUTIVE ACKNOWLEDGES THAT, BY SIGNING THIS AGREEMENT, HE IS WAIVING ANY RIGHT THAT HE MAY HAVE TO A JURY TRIAL OR A COURT TRIAL RELATED TO THIS AGREEMENT.
|
(k) Executive hereby represents and warrants to the Company that (i) the execution, delivery and performance of this Agreement by Executive do not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order,
11
|
judgment or decree to which Executive is a pa rty or by which he/she is bound and ( ii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Executive on and after the Effective Date, enforceable in accordance with its terms. Executive hereby acknowledges and represents that he has had the opportunity to consult with independent legal counsel or other advisor of his choice and has done so regarding his rights and obligations under this Agreement, that he is entering into this Agreement knowingly, voluntarily, and of his own free will, that he is relying on his own judgment in doing so, and that he fully understands the terms and conditions contained herein. |
|
(l) The Company shall have the right to withhold from any amount payable hereunder any Federal, state and local taxes in order for the Company to satisfy any withholding tax obligation it may have under any applicable law or regulation. |
|
(m) The covenants and obligations of the Company under Sections 11 , 1 6 , 1 7 and 1 8 hereof, and the covenants and obligations of Executive under Sections 11, 13, 14, 15, 16, 17 and 1 8 hereof, shall continue and survive any expiration of the Term, termination of Executive’s employment or any termination of this Agreement. |
[ signature page follows ]
EXECUTION VERSION
RESTRICTED STOCK UNIT AWARD AGREEMENT
THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (this “ Award Agreement ”) is made effective as of April 13, 2015 (the “ Grant Date ”) by and between UHS Holdco, Inc., a Delaware corporation (the “ Company ”), and Thomas Leonard (the “ Grantee ”). Capitalized terms used but not defin ed herein, including in Section 8 , shall have the meanings ascribed to such terms in the Employment Agreement.
R E C I T A L S :
WHEREAS, the Board of Directors of the Company (the “Board”) has determined that it would be in the best interests of the Company and its stockholders to grant the restricted stock units provided for herein to the Grantee pursuant to the terms set forth herein.
NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties agree as follows:
|
1. Restricted Stock Unit Award . Subject to the terms and conditions of this Award Agreement, the Company hereby grants to the Grantee 7,042,254 restricted stock units (the “ RSUs ”), which shall vest in accordance with Section 2 hereof. Each RSU represents one notional S hare. |
|
2. Vesting and Forfeiture . |
|
(a) Vesting Schedule . Twenty-five percent (25%) of the RSUs shall vest on each of the first four anniversaries of the Grant Date ( each anniversary, a “ Vesting Date ”), provided that a Termination Date has not occurred prior to the applicable Vesting Date . |
|
(b) Forfeiture . In the event that a Termination Event occurs prior to a Vesting Date, all unvested RSUs shall be cancelled for no consideration . In the event that Grantee ’s Service terminates for C ause, any Shares issued in settlement of RSUs shall be forfeited and cancelled for no consideration . |
|
(c) Change of Control . In the event of a Change of Control or a Sale of the Company pursuant to clause (ii) of the definition below, all RSUs shall vest . |
|
3. Settlement of RSUs . Within fifteen (15) days following an applicable Vesting Date (each such date, a “ Settlement Date ”) , the Company shall cause the number of Shares equal to the number of RSUs that vested on the Vesting Date to be issued in the name of the Grantee . RSUs shall be settled in all events no later than March 15 th of the year following the year in which the RSUs vest. The Company shall not be liable to the Grantee for damages relating to any delays in issuing the certificates to the Grantee , any loss of the certificates, or any mistakes or errors in the issuance of the certificates or in the certificates themselves. The Grantee shall have none of the rights of a stockholder of the Company with respect to the RSUs unless and until Shares are issued to the Grantee in accordance with this Section 3 . As of the Grant Date, the Grantee shall enter into a joinder to the Stockholders Agreement (if not already a party to the Stockholders Agreement) substantially in the form attached hereto as Exhibit A , to become effective upon the settlement of the RSUs by the delivery of Shares. |
On each Settlement Date t he Grantee shall be permitted to elect to satisfy all or part of the minimum applicable income and employment tax withholdings (“ Withholding Amount ”) in connect ion with the settlement of RSUs by any combination of: (i) having Shares otherwise deliverable in settlement of such RSUs, having a Fair Market Value equal to the amount of such withholdings, withheld by the Company on the date such RSUs are settled and (ii) borrow ing an amount equal to all or a portion of the Withholding Amount from the Company pursuant to a p romissory note substantially i n the form provided in Exhibit B .
|
4. No Right to Continued Service . The granting of the RSU evidenced hereby and this Award Agreement shall impose no obligation on the Company or any Affiliate to continue the Service of the Grantee and shall not lessen or affect any right that the Company or any Affiliate may have to terminate the Service of such Grantee . |
|
5. Securities Laws/Legend on Certificates . The issuance and delivery of Shares shall comply (or be exempt from) all applicable requirements of law, including (without limitation) the Securities Act of 1933, as amended, the rules and regulations promulgated thereunder, state securities laws and regulations, and the regulations of any stock exchange or other securities market on which the Company’s securities may then be traded. The Company shall not be obligated to file any registration statement under any applicable securities laws to permit the purchase or issuance of any Shares, and accordingly any certificates fo r Shares or documents granting equity a wards may have an appropriate legend or statement of applicable restrictions endorsed thereon. If the Company deems it necessary to ensure that the issuance of securities under this Award Agreement is not required to be registered under any applicable securities laws, each Grantee to whom such security would be issued shall deliver to the Company an agreement or certificate containing such representations, warranties and covenants as the Company which satisfies such requirements. |
|
6. Dividend Equivalent . With respect to each RSU the Grantee shall have the right to receive an amount equal to the regular per share dividend or cash distribution (if any) paid by the Company during the period between the Grant Date and the date the RSUs are settled. When such dividends or distributions are paid by the Company, the Grantee shall be credited with an amount determined by multiplying the number of RSUs by the per share dividend or distribution, which amount shall be held by the Company and subject to forfeiture until the RSUs vest in accordance with Section 2 hereof. Such dividends and distributions shall be paid to the Grantee on the date the RSUs vest or as soon as practicable, but in no event later than thirty (30) days thereafter. |
|
7. Restrictions . The Grantee ack nowledges that the RSUs are not issued under the Company’s Amended and Restated Stock Option Plan (the “ Plan ”) , however, Sections 5.7, 5.8, 5.9, 5.10 5.11 and 6.5 of the Plan are incorporated herein by reference and Shares issued in settlement of RSUs are subject to su ch S ections of the Plan as if such Shares were issued upon the exercise of an option awarded under the Plan. |
|
8. Definitions . |
“ Affiliate ” means, when used with reference to a specified Person, any Person that directly or indirectly controls or is controlled by or is under common control with the specified Person. As used in this definition, "control" (including, with its correlative meanings, "controlled by" and "under common control with") shall mean possession, directly or indirectly, of power to direct or cause the direction of management or policies (whether through ownership of securities
2
or partnership or other ownership interests, by contract or otherwise). With respect to any Person who is an individual, "Affiliates" shall also include, without limitation, any member of such individual's Family Group.
“ Cause ” means, as defined in Grantee’s Employment Agreement.
“ Change of Control ” means any (i) sale or issuance (or series of sales or issuances) of Shares or the right to acquire Shares by the Company or any holders thereof which results in any Person or group of Affiliated Persons (other than the owners of Shares or the right to acquire Shares as of the date hereof and Affiliates of such Persons) owning and/or having the right to acquire more than 50% of the Shares on a fully diluted basis at the time of such sale or issuance (or series of sales or issuances), other than in connection with a Public Offering or (ii) merger, share exchange, reorganization, recapitalization or consolidation to which the Company is a party (other than a merger in which the Company is the surviving entity, or a share exchange in which capital stock of the Company is issued, that does not result in more than 49% of the Company’s outstanding capital stock possessing the voting power (under ordinary circumstances) to elect a majority of the Board being owned of record or beneficially by persons or entities other than the holders of such capital stock immediately prior to such merger or share exchange).
“ Code ” means the Internal Revenue Code of 1986, as amended.
“ Employment Agreement ” means that certain employment agreement between UHS and Grantee dated as of April 8 , 2015 , as ma y be amended from time to time.
“ Fair Market Value ” of any Share as of any given date shall be determined in good faith by the Board based on such factors as the Board, in the exercise of its reasonable business judgment, considers relevant; provided , that in making such determination, the Board shall assume that the Company and its Subsidiaries are sold as a going concern and then liquidated and shall not provide for any discounts based on the fact that the Shares being valued represent a minority interest in the Company; provided , further , that notwithstanding anything herein to the contrary, any determination of Fair Market Value shall be made in accordance with the requirements of Section 409A of the Code.
“ Family Group ” means, when used with reference to a specified individual Person, (i) such Person's spouse, former spouse, ancestors and descendants (whether natural or adopted), parents and their descendants and any spouse of the foregoing persons (collectively, “relatives”), (ii) the trustee, fiduciary or personal representative of such Person and any trust solely for the benefit of such Person and/or such Person's relatives (other than any remainder interests) or (iii) any limited partnership or limited liability company the governing instruments of which provide that such Person shall have the exclusive, nontransferable power to direct the management and policies of such entity and of which the sole owners of partnership interests, membership interests or any other equity interests are, and will remain, limited to such Person and such Person's relatives.
“ Good Reason ” means, as defined in the Grantee’s Employment Agreement.
“ Independent Third Party ” means any Person who, immediately prior to the contemplated transaction, does not own in excess of 5% of the Shares on a fully diluted basis, who is not
3
controlling, controlled by or under common control with any such 5% owner of the Shares and who is not the spouse or descendant (by birth or adoption) of any such 5% owner of the Shares .
“ Person ” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, a governmental entity or any department, agency or political subdivision thereof or any other entity or organization.
“ Public Offering ” means an underwritten public offering and sale of Shares pursuant to an effective registration statement under the Securities Act; provided , that a Public Offering shall not include an offering made in connection with a business acquisition or combination pursuant to a registration statement on Form S-4 or any form for similar registration purposes, or an employee benefit plan pursuant to a registration statement on Form S-8 or any form for similar registration purposes.
“ Sale of the Company ” means any transaction (other than pursuant to a Public Offering) involving the Company or UHS and an Independent Third Party or affiliated group of Independent Third Parties pursuant to which such party or parties acquire (i) a majority of the outstanding shares of capital stock of the Company or UHS (whether by merger, consolidation, sale of the capital stock or otherwise) or (ii) all or substantially all of the assets of the Company or UHS, as determined on a consolidated basis.
“ Share ” means a share of the Company’s common s tock , par value $0.01per share.
“ Stockholders Agreement ” means the Stockholders Agreement, dated as of May 31, 2007, by and among the Company and certain of the Company's stockholders, as amended or modified from time to time.
“ Subsidiary ” means, with respect to any Person, any corporation, partnership, limited liability company, association or other business entity of which (i) if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii) if a partnership, limited liability company, association or other business entity, a majority of the partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination thereof. For purposes hereof, a Person or Persons shall be deemed to have a majority ownership interest in a partnership, limited liability company, association or other business entity if such Person or Persons shall be allocated a majority of partnership, limited liability company, association or other business entity gains or losses or shall be or control the managing director, managing member, manager or a general partner of such partnership, limited liability company, association or other business entity. Where not otherwise indicated, the term “ Subsidiary ” refers to a Subsidiary of the Company.
“ Termination Date ” means, with respect to the Grantee , the date that a Termination Event has occurred.
4
“ Termination Event ” means that Grantee has ceased to be employed by the Company or any of its Subsidiaries for any reason or no reason (including as a result of such Grantee 's disability or death, resignation for Good Reason or termination by UHS with or without Cause. )
“ UHS ” means Universal Hospital Services, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company.
|
9. Restrictive Covenants . The Grantee acknowledges that the RSUs shall serve as additional consideration for the rest rictive covenants in Section 15 of the Employment Agreement. |
|
10. Withholding . The Grantee may be required to pay to the Company or any Affiliate and the Company shall have the right and is hereby authorized to withhold the minimum statutory withholding taxes in respect of the RSU, its settlement or any payment or transfer under or with respect to the RSU and to take such other action as may be necessary in the opinion of the Committee to satisfy all obligations for the payment of such withholding taxes. |
|
11. Notices . Any notice hereunder to the Company shall be addressed to the Company’s principal executive office, Attention: General Counsel, and any notice hereunder to Grantee shall be addressed to Grantee at Grantee’s last address on the records of the Company, subject to the right of either party to designate at any time hereafter in writing some other address. Any notice shall be deemed to have been duly given when delivered personally, one day following dispatch if sent by reputable overnight courier, fees prepaid, or three days following mailing if sent by registered mail, return receipt requested, postage prepaid and addressed as set forth above. |
|
12. Entire Agreement . The Award Agreement (including the provisions of the Stockholders Agreement and the Plan incorporated by reference herein) constitute the entire contract between the parties hereto with regard to the subject matter hereof. They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) which relate to the subject matter hereof. |
|
13. Waiver . No waiver of any breach or condition of this Award Agreement shall be deemed to be a waiver of any other or subsequent breach or condition whether of like or different nature. |
|
14. Successors and Assigns . The provisions of this Award Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and upon the Grantee , the Grantee’s assigns and the legal representatives, heirs and legatees of the Grantee’s estate, whether or not any such person shall have become a party to this Award Agreement and have agreed in writing to be joined herein and be bound by the terms hereof. |
|
15. Choice of Law . All issues and questions concerning the construction, validity, interpretation and enforceability of this Award Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. The parties hereto hereby irrevocably and unconditionally submit to the exclusive jurisdiction of any Federal court sitting in the State of Minnesota over any suit, action or proceeding arising out of or relating to this Plan. The parties hereby agree that service of any process, summons, notice or document by U.S. registered mail addressed to any such party shall be effective service of process for any action, suit or proceeding brought against a party in any such court. The parties hereto
5
|
hereby irrevocably and unconditionally waive any objection to the laying of venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. The parties hereto agree that a final judgment in any such suit, action or proceeding brought in any such court shall be conclusive and binding upon any party and may be enforced in any other courts to whose jurisdiction any party is or may be subject, by suit upon such judgment. |
|
16. No Guarantees Regarding Tax Treatment . The Grantee (or their beneficiaries) shall be responsible for all taxes with respect to the RSUs. The Committee and the Company make no guarantees regarding the tax treatment of the RSUs. |
|
17. Amendment . The Committee may amend or alter this Award Agreement and the RSUs granted hereunder at any ti me; provided that , no such amendment or alteration shall be made without the consent of the Grantee if such action would materially diminish any of the rights of the Grantee under this Award Agreement or with respect to the RSU s . |
|
18. Severability . The provisions of this Award Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable. |
|
19. Signature in Counterparts . This Award Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. |
* * *
6
IN WITNESS WHEREOF, the parties hereto have executed this Restricted Stock Unit Award Agreement as of the date first written above.
UHS HOLDCO , INC.
/s/ James B. Pekarek
By: James B. Pekarek
Agreed and acknowledged as
of the date first above written:
/s/ Thomas Leonard
GRANTEE
EXHIBIT A
JOINDER TO STOCKHODLERS AGREEMENT
EXHIBIT B
FORM OF PROMISSORY NOTE
UHS HOLDCO, INC.
FORM OF OPTION AGREEMENT
EVIDENCING A GRANT OF AN OPTION UNDER
THE
2007 STOCK O
PTION PLAN
This Option Agreement (this “ Agreement ” ) is made May 8 , 201 5 (the “ Grant Date ”) , between UHS Holdco, Inc., a Delaware corporation (the “ Company ” ), and Thomas Leonard ( “ Grantee ” ). Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Plan (as defined below); provided that any capitalized terms used herein or in the Plan that are defined in the employment agreement between Universal Hospital Services, Inc. and Grantee dated as of April 8, 2015 (the “ Employment Agreement ”), shall have the meanings assigned to such terms in the Employment Agreement.
|
1. Grant of Option. Pursuant to the UHS Holdco, Inc. Stock Option Plan (the “ Plan ” ), the Company hereby grants to Grantee, as of the date hereof, a stock option (the “ Option ” ) to purchase from the Company 15,000,000 shares (the “ Shares ” ) of the Company ’ s common stock, $0.01 par value per share (the “ Common Stock ” ), at the exercise price per share of $ 0.71 (the “ Exercise Price ” ), subject to the terms and conditions set forth herein and in the Plan. Upon certain events, the number of Shares and/or the Exercise Price may be adjusted as provided in the Plan. |
|
2. Grantee Bound by Plan. The Plan is incorporated herein by reference and made a part hereof. Grantee hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof. The Plan should be carefully examined before any decision is made to exercise the Option. |
|
4. Expiration of Option. The Option shall not be exercisable in any event after November 4, 2024 (the “ Expiration Date ”) . Any part of the Option that is not vested on the Termination Date shall expire and be forfeited on such date, and any part of the Option that is vested on the Termination Date shall also expire and be forfeited to the extent not exercised on or before 90 days following the Termination Date or such shorter period if such 90 ‑day period would exceed the original term of the Option; provided , that in the event of the death or disability of the Grantee, any part of the Option that is vested on the date of the Termination Date shall expire and be forfeited to the extent not exercised on or before 180 days following the Termination Date or such shorter period if such 180 ‑day period would exceed the original term of the Option. |
|
(a) The Option shall fully vest and become exercisable with respect to the applicable number of Shares set forth below if and only if the Termination Date does not occur
|
during the period beginning on the date hereof and ending on the applicable vesting dat e determined below. The Option shall cumulatively vest and become exercisable with respect to 20 % of the Shares (rounded to the nearest one ‑thousandth (0.001) of a share of Common Stock) on each of the first five (5) anniversaries of the Grant Date . |
|
(b) Upon (i) a Change in Control (as defined below) or (ii) a Sale of the Company pursuant to clause (ii) of the definition thereof set forth in the Plan, 100% of any portion of the Option that is not vested as of the date of such Change in Control or such Sale of the Company, as applicable, shall become vested and immediately exercisable and, subject to Sections 5.10 and 6.4 of the Plan, shall remain exercisable for a period of 90 days following such Change in Control or such Sale of the Company, as applicable. For the purposes hereof, “ Change in Control ” means any (i) sale or issuance (or series of sales or issuances) of Common Stock or the right to acquire Common Stock by the Company or any holders thereof which results in any Person or group of Affiliated Persons (other than the owners of Common Stock or the right to acquire Common Stock as of the date hereof and Affiliates of such Persons) owning and/or having the right to acquire more than 50% of the Common Stock on a fully diluted basis at the time of such sale or issuance (or series of sales or issuances), other than in connection with a Public Offering or (ii) merger, share exchange, reorganization, recapitalization or consolidation to which the Company is a party (other than a merger in which the Company is the surviving entity, or a share exchange in which capital stock of the Company is issued, that does not result in more than 49% of the Company ’ s outstanding capital stock possessing the voting power (under ordinary circumstances) to elect a majority of the Board being owned of record or beneficially by persons or entities other than the holders of such capital stock immediately prior to such merger or share exchange). |
|
6. Conditions to Exercise. The Option may not be exercised by Grantee unless the following conditions are met: |
|
(a) The Option has become vested with respect to the Shares to be acquired pursuant to such exercise; |
|
(b) Legal counsel for the Company must be satisfied at the time of exercise that the issuance of shares of Common Stock upon exercise will be in compliance with the Securities Act and applicable United States federal, state, local and foreign laws ; provided that, if the shares of Common Stock are not issued upon exercise because the Company’s legal counsel is not satisfied at the time of exercise that the issuance of shares of Common Stock will be in compliance with the Securities Act and applicable United States, federal , state, local and foreign laws, the exercise period applicable to the Option shall be tolled from the date of exercise until the determination is made by the Company’s legal counsel that the issuance of shares of Common Stock will be in compliance with the Securities Act and applicable laws , but in no event, later than the Expiration Date ; and |
|
(c) Grantee must pay at the time of exercise the full Exercise Price for the Shares being acquired hereunder in the form elected by Grantee, plus any withholding tax (which shall be paid only in cash) required in connection with such exercise, in each case, in accordance with the terms of the Plan. |
|
8. Administration. Any action taken or decision made by the Company, the Board, or the Committee or its delegates arising out of or in connection with the construction, administration, interpretation or effect of the Plan or this Agreement shall lie within its sole and absolute discretion, as the case may be, and shall be final, conclusive and binding on Grantee and all persons claiming under or through Grantee, except as expressly provided in Grantee ’ s Employment Agreement , if any, with the Company or any of its Subsidiaries. By accepting this grant or other benefit under the Plan, Grantee and each person claiming under or through Grantee shall be conclusively deemed to have indicated acceptance and ratification of, and consent to, any action taken under the Plan by the Company, the Board or the Committee or its delegates. |
|
9. No Rights as Stockholder. Unless and until a certificate or certificates representing such shares of Common Stock shall have been issued to Grantee (or any person acting under Section 6 above), Grantee shall not be or have any of the rights or privileges of a stockholder of the Company with respect to shares of Common Stock acquirable upon exercise of the Option. |
|
10. Investment Representation. Grantee hereby acknowledges that the shares of Common Stock which Grantee may acquire by exercising the Option shall not be Transferred in the absence of an effective registration statement for the shares of Common Stock under the Securities Act and applicable state securities laws or an applicable exemption from the registration requirements of the Securities Act and any applicable state securities laws. Grantee also agrees that the shares of Common Stock which Grantee may acquire by exercising the Option will not be sold or otherwise disposed of in any manner which would constitute a violation of any applicable federal or state securities laws. |
|
11. Rights of Grantee. Neither this Agreement nor the Plan creates any employment rights in Grantee and neither the Company nor any of its Subsidiaries shall have any liability arising out of the Plan or this Agreement for terminating Grantee ’ s employment or reducing Grantee ’ s responsibilities. |
|
12. Notices. Any notice hereunder to the Company shall be addressed to the Company ’ s principal executive office, Attention: General Counsel, and any notice hereunder to Grantee shall be addressed to Grantee at Grantee ’ s last address on the records of the Company, subject to the right of either party to designate at any time hereafter in writing some other address.
|
Any notice shall be deemed to have been duly given when delivered personally, one day following dispatch if sent by reputable overnight courier, fees prepaid, or three days following mailing if sent by registered mail, return receipt requested, postage prepaid and addressed as set forth above. |
|
13. Binding Effect. This Agreement shall be binding upon and inure to the benefit of any successors and assigns to the Company and all persons lawfully claiming under Grantee. |
|
14. Restrictive Covenants . The Grantee acknowledges that the Option shall serve as additional consideration for the restrictive covenant s in Section [ ] of the Employment Agreement. |
|
15. Governing Law. The validity, construction, interpretation, administration and effect of the Plan, and of its rules and regulations, and rights relating to the Plan and to this Agreement, shall be governed by the substantive laws, but not the choice of law rules, of the State of Delaware. The parties hereto hereby irrevocably and unconditionally submit to the exclusive jurisdiction of any Federal court sitting in the State of Minnesota over any suit, action or proceeding arising out of or relating to this Agreement. The parties hereby agree that service of any process, summons, notice or document by U.S. registered mail addressed to any such party shall be effective service of process for any action, suit or proceeding brought against a party in any such court. The parties hereto hereby irrevocably and unconditionally waive any objection to the laying of venue of any such suit, action or proceeding brought in any such court and any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. The parties hereto agree that a final judgment in any such suit, action or proceeding brought in any such court shall be conclusive and binding upon any party and may be enforced in any other courts to whose jurisdiction any party is or may be subject, by suit upon such judgment. |
* * * * *
Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Thomas J. Leonard , certify that:
|
1. I have reviewed this quarterly report on Form 10-Q of Universal Hospital Services , I nc. (the “ registrant ” ); |
|
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. The registrant ’ s other certifying officer (s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) for the registrant and have: |
|
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
(c) Evaluated the effectiveness of the registrant ’ s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
(d) Disclosed in this report any change in the registrant ’ s internal control over financial reporting that occurred during the registrant ’ s most recent fiscal quarter (the registrant ’ s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant ’ s internal control over financial reporting; and |
|
5. The registrant ’ s other certifying officer (s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant ’ s auditors and the audit committee of the registrant ’ s board of directors (or persons performing the equivalent functions): |
|
(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant ’ s ability to record, process, summarize and report financial information; and |
|
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant ’ s internal control over financial reporting. |
|
|
Date: May 13 , 201 5 |
/s/ Thomas J. Leonard |
|
Thomas J. Leonard |
|
Chief Executive Officer |
|
(Principal Executive Officer) |
Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, James B. Pekarek, certify that:
|
1. I have reviewed this quarterly report on Form 10-Q of Universal Hospital Services, Inc. (the “ registrant ” ); |
|
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. The registrant ’ s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
(c) Evaluated the effectiveness of the registrant ’ s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
(d) Disclosed in this report any change in the registrant ’ s internal control over financial reporting that occurred during the registrant ’ s most recent fiscal quarter (the registrant ’ s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant ’ s internal control over financial reporting; and |
|
5. The registrant ’ s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant ’ s auditors and the audit committee of the registrant ’ s board of directors (or persons performing the equivalent functions): |
|
(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant ’ s ability to record, process, summarize and report financial information; and |
|
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant ’ s internal control over financial reporting. |
|
|
Date: May 13 , 2015 |
/s/ James B. Pekarek |
|
James B. Pekarek |
|
Executive Vice President and |
|
Chief Financial Officer |
|
(Principal Financial Officer) |
CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Universal Hospital Services , I nc. (the “ Company ” ) on Form 10-Q for the period ended March 31, 2015 , as filed with the Securities and Exchange Commission (the “ Report ” ) , I , Thomas J. Leonard , Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and |
|
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
|
Date: May 13 , 2015 |
/s/ Thomas J. Leonard |
|
Thomas J. Leonard |
|
Chief Executive Officer |
CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Universal Hospital Services, Inc. (the “ Company ” ) on Form 10-Q for the period ended March 31, 2015 , as filed with the Securities and Exchange Commission (the “ Report ” ), I, James B. Pekarek, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
|
Date: May 13 , 2015 |
/s/ James B. Pekarek |
|
James B. Pekarek |
|
Executive Vice President and |
|
Chief Financial Officer |